EP3749685A1 - Récepteurs chimériques activateurs et leurs utilisations dans une immunothérapie par cellules tueuses naturelles - Google Patents

Récepteurs chimériques activateurs et leurs utilisations dans une immunothérapie par cellules tueuses naturelles

Info

Publication number
EP3749685A1
EP3749685A1 EP19750469.9A EP19750469A EP3749685A1 EP 3749685 A1 EP3749685 A1 EP 3749685A1 EP 19750469 A EP19750469 A EP 19750469A EP 3749685 A1 EP3749685 A1 EP 3749685A1
Authority
EP
European Patent Office
Prior art keywords
polynucleotide
cells
domain
several embodiments
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19750469.9A
Other languages
German (de)
English (en)
Other versions
EP3749685A4 (fr
Inventor
See Voon Seow
Dario Campana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National University of Singapore
Original Assignee
National University of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National University of Singapore filed Critical National University of Singapore
Publication of EP3749685A1 publication Critical patent/EP3749685A1/fr
Publication of EP3749685A4 publication Critical patent/EP3749685A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Definitions

  • Immunotherapy is the use and manipulation of the patient’s immune system for treatment of various diseases.
  • Immunotherapy presents a new technological advancement in the treatment of disease, wherein immune cells are engineered to express certain targeting and/or effector molecules that specifically identify and react to diseased or damaged cells. This represents a promising advance due, at least in part, to the potential for specifically targeting diseased or damaged cells, as opposed to more traditional approaches, such as chemotherapy, where all cells are impacted, and the desired outcome is that sufficient healthy cells survive to allow the patient to live.
  • One immunotherapy approach is the recombinant expression of activating chimeric receptors in immune cells to achieve the targeted recognition and destruction of aberrant cells of interest.
  • a polynucleotide encoding an activating chimeric receptor comprising an extracellular receptor domain and an effector domain comprising a transmembrane region and an intracellular signaling domain, wherein the extracellular receptor domain comprises a peptide that binds an immune antigen with high affinity.
  • a polynucleotide encoding an activating chimeric receptor that comprises an extracellular receptor domain that comprises an engineered variant of Natural Killer Group 2 member C (NKG2C) having higher affinity for an immune ligand of NKG2C.
  • the polynucleotide is designed to impart to the encoded NKG2C variant an enhanced binding affinity for an immune ligand, such as the HLA-E/peptide complex, relative to native NKG2C, whereas a non-engineered NKG2C has lower binding affinity for HLA-E/peptide complex.
  • an engineered NKG2C variant is used in the absence of a native or engineered NKG2A variant.
  • full length, or other native truncated form of, NKG2C is not used.
  • a polynucleotide encoding an activating chimeric receptor that comprises or an extracellular receptor domain that comprises a fragment of Natural Killer Group 2 member A (NKG2A), the fragment engineered to transduce activation signals, rather than inhibitory signals, upon binding of an immune ligand, such as the HLA- E/peptide complex.
  • NKG2A Natural Killer Group 2 member A
  • an engineered NKG2A variant is used in the absence of a native or engineered NKG2C variant.
  • full length, or other native truncated form of, NKG2A is not used.
  • polynucleotide comprises an effector domain that comprises a transmembrane region and an intracellular signaling domain, those domains serving to transduces activation and/or
  • the extracellular receptor domain comprises an engineered NKG2C variant coupled to an effector domain comprising a transmembrane region and an intracellular signaling domain.
  • the engineered NKG2C variant extracellular domain is coupled to a native NKG2C transmembrane region and/or a native NKG2C intracellular signaling domain.
  • the engineered NKG2C variant comprises the amino acid sequence of SEQ ID NO. 58.
  • the engineered NKG2C variant is encoded by the nucleic acid sequence of SEQ ID NO: 63, or a fragment thereof.
  • the NKG2C variant has at least about 70%, about75%, about 80%, about 85%, about 90%, about 95%, about 98%, or about 99% homology as compared to SEQ ID NO: 63.
  • the activating chimeric receptor comprises a fragment of NKG2A coupled to an effector domain comprising a transmembrane region and an intracellular signaling domain.
  • the NKG2A fragment is coupled to a native NKG2A transmembrane region and/or a native NKG2A intracellular signaling domain.
  • the NKG2A fragment is coupled to a native NKG2C transmembrane region and/or a native NKG2C intracellular signaling domain.
  • the NKG2A fragment has the sequence of SEQ ID NO: 65.
  • the fragment of NKG2A has at least about 70%, about 75%, about 80%, about 85%, about 90%, about95%, about 98%, or about 99% homology as compared to SEQ ID NO: 65.
  • the NKG2A fragment is coupled to a CD8a transmembrane domain and an effector domain comprising one or more of 4- 1BB and CD3zeta.
  • such an activating chimeric receptor construct is encoded by the nucleic acid sequence of SEQ ID NO: 61 or comprises the amino acid sequence of SEQ ID NO: 62.
  • the polynucleotide further encodes DN AX-activating protein 12 (DAP12) or DAP10.
  • DAP10 is not included in the activating receptor construct and/or is not included in another engineered construct expressed by cells.
  • DAP12 is not included in the activating receptor construct and/or is not included in another engineered construct expressed by cells.
  • the polynucleotide encodes native CD94 or a chimeric CD94.
  • the chimeric CD94 comprises an extracellular receptor domain comprising a fragment of CD94 and an effector domain comprising a transmembrane region and an
  • a chimeric CD94 receptor comprises a fragment of CD94 coupled a CD8a transmembrane domain and an effector domain comprising one or more of 4-1BB and CD3zeta.
  • the chimeric CD94 is encoded by the nucleic acid sequence of SEQ ID NO: 59.
  • the chimeric CD94 comprises the amino acid sequence of SEQ ID NO: 60. Variants, fragments, or truncations of CD94 are also used in some embodiments.
  • a CD94 variant having at least about 70%, about75%, about 80%, about 85%, about 90%, about 95%, about 98%, or about 99% homology as compared to SEQ ID NO: 59 or 60 is used.
  • the fragment of CD94 has at least 80% homology to SEQ ID NO: 67.
  • the fragment of CD94 has at least 80% homology to SEQ ID NO: 68.
  • the effector domain comprises one or more of CD 16, NCR1, NCR2, NCR3, 4-1BB, NKp80, DAP10, CD3zeta, 2B4. Actively signaling fragments of any of these signaling moieties are also useful, according to some embodiments.
  • the activating chimeric receptor further comprises a linker and/or a hinge region.
  • these regions can function to space apart other portions of the molecule, for example to reduce steric hindrance of the receptor, and/or to reduce or eliminate functional issues that may result upon formation of tertiary structures.
  • the activating chimeric receptor comprises a GS linker that can optionally be repeated two or more times.
  • the GS linker is repeated 3, 4, 5, 6 or more times.
  • the hinge region comprises a glycine-serine repeating motif having the amino acid sequence of SEQ ID NO: 31.
  • the chimeric receptor comprises a hinge region.
  • Some embodiments employ hinges encoded by nucleic acid sequence of SEQ ID NO: 5. Additional embodiments employ a hinge region encoded by a fragment of the nucleic acid sequence of SEQ ID NO: 5.
  • the hinge region comprises the amino acid sequence of SEQ ID NO: 32 or SEQ ID NO: 33.
  • the hinge region is encoded by the nucleic acid sequence of SEQ ID NO: 34.
  • Some embodiments employ portions of the beta-adrenergic receptor as a hinge region.
  • Some embodiments employ a hinge region is encoded by the nucleic acid sequence of SEQ ID NO: 40 or of SEQ ID NO: 42.
  • a signal peptide is also provided.
  • the extracellular receptor domain further comprises a CD8a signal peptide, wherein the signal peptide comprises the nucleic acid sequence of SEQ ID NO. 4.
  • the effector domain is configured to include one or more hemi- ITAM sequences.
  • the hemi-ITAM comprises either the amino acid sequence of SEQ ID NO. 14 or the amino acid sequence of SEQ ID NO. 37.
  • the ultimate construct encoded by the polynucleotide may utilize a mixture of the sequences (e.g., hetero-tandem signaling domains).
  • the effector domain comprises one or more ITSM sequences.
  • the ITSM in several embodiments, comprises the amino acid sequence of SEQ ID NO. 15 and/or the amino acid sequence of SEQ ID NO. 35
  • the polynucleotide further encodes a chimeric receptor comprising an extracellular receptor domain that binds native ligands of Natural Killer Group 2 member D (NKG2D) and an effector domain comprising a transmembrane region and an intracellular signaling domain that serve to transduce signals to a cell expressing the chimeric receptor upon binding of an NKG2D ligand.
  • the chimeric receptor does not employ full-length or wild-type NKG2D, but rather a fragment of NKG2D that retains the ability to bind one or more ligands of NKG2D.
  • the chimeric receptor that binds NKG2D is provided on a separate polynucleotide from that encoding the activating receptor (yet ultimately both can be co-expressed in a single cell).
  • the polynucleotide also encodes a short hairpin RNA
  • shRNA that specifically inhibits transcription or translation of native NKG2A.
  • the shRNA that inhibits transcription or translation of native NKG2A results in a reduced, if not eliminated, expression of NKG2A on cells expressing the polynucleotide. In some embodiments, this reduces the competition for an immune antigen between the higher affinity NKG2A and NKG2C.
  • the relatively lower affinity NKG2C receptor is able to bind an immune antigen (such as the HLA-E/peptide complex) and transduce activating signals to the cell (such as an NK cell).
  • the shRNA comprises a nucleotide sequence that hybridizes under stringent conditions to the native NKG2A gene and comprises a sense fragment being substantially identical to a target sequence in the NKG2A gene (that target sequence being absent from the NKG2A fragment), and an antisense fragment, wherein the sense and antisense fragments are separated by a loop fragment.
  • Other mechanisms to reduce native NKG2A receptor expression can also be employed, depending on the embodiment.
  • a separate vector could be used that comprises antisense sequences to disrupt native NKG2A receptor production (but spares production of engineered NKG2A fragments/constructs as disclosed herein).
  • Gene editing techniques can also be employed to selective trim one or more regions of DNA encoding native NKG2A receptors. Immune or mechanical separation techniques (affinity immobilization) can also be used to selectively deplete cell populations, such as immune cells like NK or T cells, of cells expressing NKG2A receptors.
  • the provided polynucleotide encodes, or is co-expressed with an additional construct that encodes, membrane-bound interleukin 15 (mbILl5).
  • Membrane- bound IL15 facilitates, in several embodiments, the expansion of cells expressing the activating chimeric receptors disclosed herein.
  • the polynucleotide is an mRNA.
  • the polynucleotide is operably linked to at least one regulatory element for the expression of the activating chimeric receptors.
  • vectors that comprise the polynucleotides, the vectors configured to deliver and facilitate the expression of the protein encoded by the polynucleotide in a cell, such as an immune cell (e.g., a NK cell).
  • the vector is a retrovirus, such as a lentivirus or HIV. Additional embodiments provide for other vectors, such as adenovirus, adeno-associated virus and even non-viral vectors (e.g., liposomes).
  • NK cells are used.
  • autologous cells e.g., NK cells
  • allogeneic cells e.g., NK cells
  • the cell populations are enriched for high affinity activating chimeric receptors.
  • enrichment comprises converting (e.g., by expressing the polynucleotides disclosed herein) inhibitory NKG2A receptors into activating NKG2A receptors. Additionally, this conversion can be coupled with expression of engineered NKG2C receptors having increased affinity for ligands that result in NKG2C transmitting activating signals. Moreover, cell populations can be configured to lack surface expression of native NKG2A, either through genetic modulation of the nucleic acids encoding native NKG2A and/or by selective depletion of cells expressing native NKG2A from a population.
  • a genetically engineered immune cells such as a NK cell, comprising an activating chimeric receptor that is either an engineered NKG2C receptor having increased affinity for antigens or an NKG2A variant that has been converted from an inhibitory receptor to an activating receptor.
  • such cells may also include one or more of a polynucleotide encoding a chimeric receptor configured to bind native ligands of Natural Killer Group 2 member D (NKG2D) through an extracellular receptor domain (and comprising an effector domain comprising a transmembrane region and an intracellular signaling domain), a polynucleotide encoding membrane-bound interleukin 15 (mbILl5), a polynucleotide encoding a short hairpin RNA (shRNA) that specifically inhibits transcription or translation of native NKG2A or combinations thereof.
  • a polynucleotide encoding a chimeric receptor configured to bind native ligands of Natural Killer Group 2 member D (NKG2D) through an extracellular receptor domain (and comprising an effector domain comprising a transmembrane region and an intracellular signaling domain
  • mbILl5 membrane-bound interleukin 15
  • shRNA short hairpin RNA
  • Various immune cells are employed depending on the embodiment.
  • NK cells are used.
  • autologous cells e.g., NK cells
  • engineered to express the activating chimeric receptors are provided.
  • Additional embodiments provide for allogeneic cells (e.g., NK cells) engineered to express the activating chimeric receptors disclosed herein.
  • the methods further comprise depleting a population of cells to be administered to a subject of cells expressing native NKG2A. In several embodiments, depletion results in a 20%, 25%, 30%, 40%, or 50% (or more) reduction in cells expression native NKG2A.
  • the enhanced immune cell-based cytotoxicity is used in treating or preventing cancer or an infectious disease.
  • the activating chimeric receptor in the manufacture of a cell-based medicament for enhancing Natural Killer (NK) cell cytotoxicity.
  • the activating chimeric receptor can be an engineered NKG2C receptor having increased affinity for antigens or an NKG2A variant that has been converted from an inhibitory receptor to an activating receptor.
  • both engineered NKG2C and NKG2A variants are used in manufacture of a medicament for the treatment of cancer or an infectious disease.
  • compositions and related methods summarized above and set forth in further detail below describe certain actions taken by a practitioner; however, it should be understood that they can also include the instruction of those actions by another party.
  • actions such as “administering a population of NK cells expressing an activating chimeric receptor” include “instructing the administration of a population of NK cells expressing an activating chimeric receptor.”
  • FIGs. 1A-1B depict an engineered receptor according to several embodiments disclosed herein.
  • FIG. 1 A depicts a schematic showing an engineered Natural Killer Group 2 C (NKG2C) variant engineered for high affinity to HLA-E/peptide complex (165-168 SIIS) in a complex with CD94 and a Dap 12 dimer (termed“Dl2(SIIS)2C94” herein), according to several embodiments disclosed herein.
  • FIG. 1 A depicts a schematic showing an engineered Natural Killer Group 2 C (NKG2C) variant engineered for high affinity to HLA-E/peptide complex (165-168 SIIS) in a complex with CD94 and a Dap 12 dimer (termed“Dl2(SIIS)2C94” herein), according to several embodiments disclosed herein.
  • FIG. 1 A depicts a schematic showing an engineered Natural Killer Group 2 C (NKG2C) variant engineered for high affinity to HLA-E/peptide complex (165-168 SIIS)
  • FIG. 1B depicts a schematic of a construct comprising NKG2C (165-168 SIIS), Dapl2, and CD94 inserted into a MSCY retroviral vector containing green fluorescence protein (GFP) after an internal ribosomal entry site (IRES), according to several embodiments disclosed herein.
  • NKG2C 165-168 SIIS
  • Dapl2 Dapl2
  • CD94 a MSCY retroviral vector containing green fluorescence protein (GFP) after an internal ribosomal entry site (IRES), according to several embodiments disclosed herein.
  • FIGs. 2A-2F depict flow cytometry data related to the expression of the high affinity activating Dl2(SIIS)2C94 receptor complex in purified NKG2C(+)NKG2A(-) NK cells.
  • the Dl2(SIIS)2C94 expression profiles of NK cells transduced with a vector containing GFP only (FIGs. 2A-2C) andNK cells transduced with a vector containing Dl2(SIIS)2C94 (FIGs. 2D-2F) are depicted.
  • FIGs. 3 A-3B depict the design and generation of a HLA-G signal peptide containing
  • FIG. 3 A depicts the substitution of HLA-E signal peptide with HLA-G signal peptide of HLA-E (designated as GpHLA-E; HLA-G signal peptide carrying HLA-E).
  • FIG. 3B depicts flow cytometry data related to the exogenous expression of GpHLA-E in solid tumor cell lines HT29, U20S, ES8, and EW8.
  • FIGs. 4A-4C depicts data related to 4-hour cytotoxicity assays at the indicated E:T ratios of purified NKG2C(+)NKG2A(-) NK cells that are transduced with Dl2(SIIS)2C94 against the genetically-modified tumor cell lines HT29-GpHLA-E (FIG. 4A), U20S-GpHLA-E (FIG. 4B), and SKBR3 -GpHLA-E (FIG. 4C).
  • FIGs. 5A-5B depict data related to characterization of transduced NK cells.
  • FIG. 5 A depicts flow cytometry data related the NKG2A depletion of NK cells to generate a population of NKG2A(-) NK cells.
  • FIG. 5B depicts data related to cytotoxicity assays, at the indicated E:T ratios, of mock transduced NKG2A(-) NK cell populations or Dl2(SIIS)2C94-transduced NKG2A(-) NK cells against the genetically-modified tumor cell lines (i) HT29-GpHLA-E and (ii) U20S-GpHLA-E, incubated with or without anti-NKG2A antibody Z199.
  • FIGs. 6A-6B depict schematics of an embodiment of a chimeric receptor as disclosed herein.
  • FIG. 6 A depicts a schematic showing truncated forms of Natural Killer Group 2 member A (NKG2A) and CD94 wherein there is a deletion of the N-terminus portion of the
  • FIG. 6B depicts schematics of constructs comprising chimeric CD94 and activating NKG2A receptor inserted into a MSCV retroviral vector containing green fluorescence protein (GFP) after an internal ribosomal entry site (IRES), according to several embodiments disclosed herein.
  • GFP green fluorescence protein
  • IRS internal ribosomal entry site
  • FIGS. 7A-7C depict flow cytometry data related to the expression of activating NKG2A/CD94-4lBB-CD3z receptor in transduced NKG2A-depleted NK cells (bottom row) and in mock transduced NK cell populations (top row).
  • FIGs. 8A-8B depict data related to 4-hour cytotoxicity assays atthe indicated E:T ratios of mock transduced NK cell populations or expanded NK cells expressing activating NKG2A/CD94-4lBB-CD3z receptor against (a) U20S-GpHLA-E cells (FIG. 8 A) and HT29- GpHLA-E cells (FIG. 8B).
  • FIG. 9 provides non-limiting embodiments of constructs and portions thereof according to several embodiments of the invention.
  • FIG. 10 depicts data related to a xenograft model of colorectal adenocarcinoma and the anti-tumor activity of NK-cell constructs according to several embodiments disclosed herein.
  • FIG. 11 depicts survival data from a xenograft model of colorectal adenocarcinoma after administration of NK-cell constructs according to several embodiments disclosed herein.
  • a goal of immunotherapy is to initiate or augment the response of the patient’s immune system, for example, to boost the ability of immune cells, such as Natural Killer (NK) cells to damage, kill, or otherwise inhibit damaged or diseased cells.
  • NK Natural Killer
  • One immunotherapy approach is the recombinant expression of activating chimeric receptors in immune cells for targeted recognition and destruction of the aberrant cells.
  • chimeric receptors comprise an extracellular receptor domain that recognizes ligands on target cells, an anchoring
  • transmembrane domain and an effector domain that transduces activating signals upon ligand binding.
  • Some embodiments disclosed herein utilize activating chimeric receptors having that general structure, or having variations in that general structure.
  • the transmembrane domain and the effector domain are separate peptides fused together.
  • the transmembrane and the effector domain are derived from the same peptide.
  • the transmembrane and effector domains comprise a single peptide (e.g., one peptide that passes through the membrane and is also poised to initiate a signaling cascade).
  • activating chimeric receptor constructs that exhibit a desired degree of expression in an immune cell (e.g., an NK cell), induce cytotoxic activity from the NK cell, balanced with a degree of target avidity that avoids adverse effects on non-target cells.
  • an immune cell e.g., an NK cell
  • the recombinant expression of activating chimeric receptors as disclosed herein on the surface of immune cells can redirect the targeting of immune cells to aberrant cells of interest as well as augment the immune activation upon engagement.
  • compositions comprising engineered NK cells enjoy several advantages. For example, either autologous or donor-derived allogeneic cells can be employed with an NK cell approach. Additionally, according to several embodiments, the engineered NK cells as provided for herein do not significantly increase cytotoxicity against normal cells. Further, NK cells have a significant cytotoxic effect, once activated.
  • NK cells as provided for herein, are able to further elevate that cytotoxic effect, thus providing an even more effective means of selectively killing diseased target cells. Accordingly, in several embodiments, there is provided a method of treating or preventing cancer or an infectious disease, comprising administering a therapeutically effective amount of NK cells expressing the activating chimeric receptors described herein.
  • the NK cells administered are autologous cells.
  • the NK cells administered are donor-derived
  • a recombinant NK cell e.g., by binding to a ligand on a target cell
  • an activating chimeric receptor leads to the direct killing of the stressed and/or aberrant cell (e.g., tumor cells, virally-infected cells, etc.) by cytolysis.
  • a method of enhancing NK cell cytotoxicity comprising administering NK cells engineered to express the activating chimeric receptors described herein.
  • the NK cells administered are autologous cells.
  • the NK cells are donor-derived (allogenic) cells.
  • engineered NK cells lead to indirect destruction or inhibition of stressed and/or aberrant cell (e.g., tumor cells, virally-infected cells, etc.).
  • stressed and/or aberrant cell e.g., tumor cells, virally-infected cells, etc.
  • NK cells recognize and destroy aberrant cells, including tumor cells and/or virally-infected cells.
  • the cytotoxic activity of these innate immune cells is regulated by the balance of signaling from inhibitory and activating receptors, respectively, that reside on the cell surface.
  • the former bind“self’-molecules expressed on the surface of healthy cells while the latter bind ligands expressed on aberrant cells.
  • the underlying logic is that an inhibitory receptor on an NK cell that interacts with a“self’ molecule is not going to be activated and thereby spares the cell bearing the“self’ molecule from destruction by the NK cell.
  • anNK cell expressing an activating receptor interacts with a“non-self’ ligand, for example on a diseased cell
  • the NK cell is activated and cytotoxic effects ensue.
  • an increased engagement of activating receptors relative to inhibitory receptors leads to NK cell activation and target cell lysis.
  • Natural Killer Group 2 members A (NKG2A) and C (NKG2C) are C-type lectin receptors expressed predominantly on the surface of NK cells receptors that influence the balance of inhibitory and activating signaling. Both NKG2A andNKG2C are capable of forming heterodimers with, for example, the integral membrane glycoprotein CD94. Further, both NKG2C/CD94 and NKG2A/CD94 bind the nonclassical MHC class I molecule HLA-E/peptide complex in humans.
  • HLA-E has a specialized role in cell recognition by NK cells, as HLA-E binds a restricted subset of peptides derived from signal peptides of classical MHC class I molecules, namely HLA-A, B, C, G. Therefore, NK cells can indirectly monitor the expression of classical MHC class I molecules through the interaction of NKG2C/CD94 and NKG2A/CD94 with HLA-E.
  • NKG2C is an activating receptor and HLA-E/peptide complex binding enables interaction between NKG2C/CD94 and ITAM-bearing adaptor protein DAP12.
  • NKG2A is an inhibitory receptor, and NKG2A/CD94 transmits inhibitory signals via an ITIM motif in its cytoplasmic domain.
  • NK cells The ability of NK cells to recognize and destroy aberrant cells, including tumor cells and/or virally-infected cells, make it a potentially useful component of immunotherapy approaches (including chimeric receptor-based immunotherapy approaches).
  • immunotherapy approaches including chimeric receptor-based immunotherapy approaches.
  • HLA-E is upregulated in multiple tumors and exposure of tumor cells to IFN gamma (which is secreted by immune cells) enhances expression of HLA-E.
  • IFN gamma which is secreted by immune cells
  • NKG2C has lower affinity for peptide complexes as compared to NKG2A, so the increased HLA-E expression on target cells can act as a“camouflage” of sorts.
  • polynucleotides encoding an activating chimeric receptor that binds HLA-E/peptide complex with enhanced affinity are provided for in several embodiments.
  • the activating chimeric receptor comprises a NKG2C variant engineered for enhanced affinity to HLA-E/peptide complex (e.g., as compared to the affinity of a non-modified NKG2C).
  • residues 165-168 of wild-type NKG2C are replaced with the corresponding residues ofNKG2A (SIIS).
  • the NKG2C variant comprises the amino acid sequence of SEQ ID NO. 58 (SIIS), where SIIS refers to Serine-Isoleucine-Isoleucine-Serine.
  • the affinity of the original NKG2A receptor is“transplanted” such that the previously lower affinity NKG2C receptor is engineered to have enhanced affinity.
  • the affinity of mutated NKG2C (as compared to non-mutated NKG2C) is increased by about 20%, by about 30%, by about 40% by about 50%, or more, depending on the embodiment.
  • polynucleotides encoding activating chimeric receptors such as a mutated NKG2C
  • the extracellular receptor domain is a fragment of a NKG2C variant that lacks its native transmembrane and/or intracellular domains, which, in several embodiments imparts to the variant still additional enhanced affinity for the HLA-E/peptide complex.
  • the NKG2C variant fragment is encoded by SEQ ID NO. 63.
  • the fragment of the NKG2C variant is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with full-length wild-type NKG2C.
  • the fragment may have one or more additional mutations (e.g., insertions, deletions, and/or conservative or non-conservative substitutions) from SEQ ID NO. 63, but retains, or in some embodiments, has enhanced, ligand-binding function.
  • the NKG2C variant fragment is provided as a dimer, trimer, or other concatameric format, such embodiments providing enhanced ligand-binding activity.
  • the sequence encoding the NKG2C variant fragment is optionally fully or partially codon optimized.
  • signal peptides are used.
  • the species or sequence of the signal peptide can vary with the construct.
  • a signal peptide derived from CD8 is used.
  • the signal peptide is from CD8a and has the sequence of SEQ ID NO. 4.
  • the polynucleotide encodes a NKG2C variant receptor and DAP12.
  • the polynucleotide encodes a NKG2C variant receptor and CD94.
  • the polynucleotide encodes a NKG2C variant receptor, CD94, and DAP12.
  • the cells are further engineered to alter expression (e.g., reduce or eliminate transcription and/or reduce or eliminate translation) of native NKG2A.
  • NKG2A is engineered to deliver activating signals upon HLA- E/peptide complex binding, as opposed to its normal delivery of inhibitory signals.
  • “NKG2A” refers to any variant, derivative, or isoform of the NKG2A gene or encoded protein, including, but not limited to, NKG2B.
  • polynucleotides encoding activating chimeric receptors are provided wherein the extracellular receptor domain is a fragment of NKG2A that lacks its native transmembrane or intracellular domains yet advantageously retains its ability to bind HLA-E/peptide complex.
  • the chimeric receptor encoded by the polypeptides disclosed herein does not comprise an ITIM, an IT AM or a hemi-ITAM/hemi-ITAM.
  • the NKG2A fragment is encoded by SEQ ID NO. 65.
  • the fragment of NKG2A is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with full-length wild-type NKG2A.
  • the fragment may have one or more additional mutations (e.g., insertions, deletions, and/or conservative or non-conservative substitutions) from SEQ ID NO.
  • the NKG2A fragment is provided as a dimer, trimer, or other concatameric format, such embodiments providing enhanced ligand-binding activity.
  • the sequence encoding the NKG2A fragment is optionally fully or partially codon optimized.
  • signal peptides are used. The species or sequence of the signal peptide can vary with the construct. However, in several embodiments, a signal peptide derived from CD8 is used. In one embodiment, the signal peptide is from CD8a and has the sequence of SEQ ID NO. 4.
  • the polynucleotide encodes an activating NKG2A receptor and a CD94 receptor.
  • CD94 is engineered to deliver activating signals upon HLA- E/peptide complex binding.
  • polynucleotides encoding activating chimeric receptors are provided wherein the extracellular receptor domain is a fragment of CD94 that lacks its native transmembrane or intracellular domains yet advantageously retains its ability to dimerize with NKG2A and NKG2C.
  • the CD94 fragment is encoded by SEQ ID NO. 67.
  • the fragment of CD94 is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with full-length wild-type CD94.
  • the fragment may have one or more additional mutations (e.g., insertions, deletions, and/or conservative or non-conservative substitutions) from SEQ ID NO. 67, but retains, or in some embodiments, has enhanced, ligand-binding function.
  • the CD94 fragment comprises the amino acid sequence of SEQ ID NO. 68.
  • the fragment of CD94 is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with full-length wild-type CD94.
  • the fragment may have one or more additional mutations (e.g., insertions, deletions, and/or conservative or non-conservative substitutions) from SEQ ID NO. 68, but retains, or in some embodiments, has enhanced, ligand binding function.
  • the CD94 fragment is provided as a dimer, trimer, or other concatameric format, such embodiments providing enhanced ligand-binding activity.
  • the sequence encoding the CD94 fragment is optionally fully or partially codon optimized.
  • signal peptides are used. The species or sequence of the signal peptide can vary with the construct. However, in several embodiments, a signal peptide derived from CD8 is used.
  • the signal peptide is from CD8a and has the sequence of SEQ ID NO. 4.
  • the polynucleotide encodes a chimeric CD94 receptor and an activating NKG2A receptor. In some embodiments, the polynucleotide encodes an activating NKG2C variant receptor and a chimeric CD94 receptor.
  • polynucleotides encoding the activating chimeric receptors disclosed herein are expressed in NKG2A depleted cell populations (for example a population of NK cells that is depleted, substantially depleted, or completely depleted of cells expressing NKG2A - e.g., immunodepletion methods).
  • the general activating chimeric receptor structure comprises at least one transmembrane domain, linking the ligand binding domain to a signaling domain(s).
  • a transmembrane domain can also serve to provide signaling function.
  • a fragment of CD94, a fragment of NKG2A, and/or NKG2C variant retains at least a portion of its normal transmembrane domain.
  • the transmembrane domain comprises at least a portion of CD8, which is a transmembrane glycoprotein normally expressed on both T cells and NK cells.
  • the transmembrane domain comprises CD8a, while in some embodiments CD8P is used.
  • the“hinge” e.g., the portion between the extracellular domain and the
  • CD8a has the sequence of SEQ ID NO. 5.
  • the CD8a can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the CD8a having the sequence of SEQ ID NO. 5.
  • CD8P has the sequence of SEQ ID NO. 6.
  • the CD8P can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the CD8P having the sequence of SEQ ID NO. 6.
  • dimers, trimers, or repeated sequences of CD8a and CD8P are used.
  • the transmembrane domain comprises CD 16, which serves as a signaling domain as well, in some embodiments.
  • CD 16 exists in two isoforms, a and b (also known as Fc gamma receptor Ilia and Illb, respectively). These receptors normally bind to the Fc portion of IgG antibodies that in turn activates NK cells.
  • the transmembrane domain comprises CDl6a, while in some embodiments CDl6b is used.
  • CDl6a has the sequence of SEQ ID NO. 7.
  • the CDl6a is truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the CDl6a having the sequence of SEQ ID NO. 7.
  • CDl6b has the sequence of SEQ ID NO. 8.
  • the CDl6b is truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the CDl6b having the sequence of SEQ ID NO. 8.
  • dimers of CDl6a and CDl6b are used.
  • the modifications to the CD 16 transmembrane domain comprise additional nucleic acid residues to increase the length of the domain.
  • CD 16 may be shortened.
  • the modifications to the length of CD 16 advantageously can facilitate enhanced ligand-receptor interactions.
  • activating chimeric receptors comprises the Natural Killer Receptor 2B4 domain (referred to herein as“2B4”, and also known as CD244), which serves as a signaling domain as well.
  • 2B4 is expressed on NK cells and regulates non major histocompatibility complex (MHC) restricted killing through interactions between this receptor and its ligands on target cells.
  • MHC non major histocompatibility complex
  • the transmembrane domain comprises 2B4, while in several embodiments the 2B4 domain is employed as an intracellular signaling domain.
  • 2B4 has the sequence of SEQ ID NO. 9.
  • the 2B4 can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the 2B4 having the sequence of SEQ ID NO. 9.
  • 2B4 is used as the sole transmembrane/signaling domain in the construct, however, in several embodiments, 2B4 can be used with one or more other domains. For example, combinations of CD16, 4-1BB, and/or 2B4 are used in some embodiments.
  • signaling is achieved through DAP10.
  • DAP10 DAP10
  • dimers of DAP 10 are used.
  • the transmembrane domain comprises DAP 10.
  • DAP 10 has the sequence of SEQ ID NO. 10.
  • DAP 10 can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the DAP10 having the sequence of SEQ ID NO. 10.
  • DAP12 can be used, as it can also transduce such signals.
  • DAP12 has the sequence of SEQ ID NO.
  • DAP12 can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the DAP12 having the sequence of SEQ ID NO. 11.
  • heterodimers of DAP 10 and DAP 12 are used. However, in some embodiments, neither DAP 10 nor DAP 12 are used, either in an NKG2A, NKG2C, or NKG2D construct.
  • signaling is provided through 4-1BB (also known as CD137 and tumor necrosis factor receptor superfamily member 9 (TNFRSF 9)).
  • 4-1BB is a co- stimulatory immune checkpoint molecule, typically functioning as a stimulatory molecule for activated immune cells (e.g., crosslinking of 4-1BB enhances T cell proliferation and cytolytic activity).
  • the function of 4-1BB is advantageously used in conjunction with NK cells.
  • 4-1BB has the sequence of SEQ ID NO. 12.
  • 4-1BB can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the 4-1BB having the sequence of SEQ ID NO. 12.
  • 4-1BB is the sole signaling domain, but as discussed above, in several embodiments, 4-1BB functions unexpectedly well in combination with one or more of the other transmembrane/signaling domains disclosed herein.
  • CD16 in conjunction with 4-1BB provides synergistic stimulation effects, resulting in particularly effective (e.g., cytotoxic) NK cells.
  • DAP10 in conjunction with 4-1BB provides synergistic stimulation effects, resulting in particularly effective (e.g., cytotoxic) NK cells.
  • DAP 10 in conjunction with 4-1BB and 2B4 provides synergistic stimulation effects, resulting in particularly effective (e.g., cytotoxic) NK cells.
  • the signaling domain comprises at least a portion of the CD3 T cell receptor complex.
  • the T cell receptor complex comprises multiple subunits, including the zeta, alpha, beta, gamma, delta, and epsilon subunits.
  • the NK cells engineered according to several embodiments disclosed herein comprise at least one of these subunits (or a fragment thereof).
  • the signaling domain comprises the CD3 zeta subunit.
  • CD3 zeta has the sequence of SEQ ID NO. 13.
  • CD3 zeta can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the CD3 zeta having the sequence of SEQ ID NO. 13.
  • the CD3 zeta is mutated (e.g., amino acid mutations, insertions, or deletions) such that the domain no longer is consistent with the canonical immunoreceptor tyrosine-based activation motif or ITAM motif.
  • the NK cells comprise an engineered receptor that does not contain an ITAM motif. In some embodiments, CD3zeta is not used.
  • the resultant engineered NK cells exhibit particularly enhanced cytotoxicity against target cells, with limited or reduced adverse side effects.
  • This results from the synergistic interactions of the various portions of the activating chimeric receptor that are used in that given embodiment.
  • CD3zeta in conjunction with 4-1BB provides synergistic stimulation effects, resulting in particularly effective (e.g., cytotoxic) NK cells.
  • CD3zeta in conjunction with 2B4 provides synergistic stimulation effects, resulting in particularly effective (e.g., cytotoxic) NK cells.
  • the signaling portion of the activating chimeric receptor comprises a portion of an ITAM, for example a hemi-tam.
  • these portions do not make up the canonical ITAM sequence, but rather comprise a portion that still can convey the signal required for NK cell cytotoxicity.
  • the hemi-tam has the sequence of SEQ ID NO. 14 (wherein X can be any residue).
  • the hemi-tam can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the hemi-tam having the sequence of SEQ ID NO. 14.
  • the activating chimeric receptor construct comprises the hemi-tam of SEQ ID NO. 14.
  • multiple hemi-tams can be used, for example in a head to tail, tail to head, head to head, or tail to tail configuration.
  • the presence of at least one hemi-tam confers enhanced signaling and cytotoxicity to the NK cells comprising an activating chimeric receptor employing the at least one hemi-tam.
  • activating chimeric receptor comprises NKp80, which is one non-limiting example of a hemi-tam.
  • additional signaling regions are used, including, for example, signaling regions derived from receptors of the signaling lymphocytic activation molecule (SLAM) family. These receptors include, but are not limited to 2B4 (discussed above). Receptors of the SLAM family share a consensus motif that is tyrosine-based, in their cytoplasmic tails. That motif is S/TxYxxL/I, which are referred to as immunoreceptor tyrosine- based switch motifs (ITSM) (SEQ ID NO. 15).
  • ISM immunoreceptor tyrosine- based switch motifs
  • the signaling region comprise a polypeptide sequence (or the nucleic acid encoding the same) comprising an ITSM motif.
  • the ITSM motif need not be fully encoded, but the signaling region is able to transmit an activation signal through SAP (or another similar pathway).
  • the ITSM motif has the sequence of SEQ ID NO. 15 (wherein X can be any amino acid residue).
  • the ITSM motif can be truncated or modified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the ITSM motif having the sequence of SEQ ID NO. 15.
  • the ITSM motif comprises the sequence of SEQ ID NO. 15.
  • the NK cells are engineered to express membrane-bound interleukin 15 (mbILl5).
  • mbILl5 membrane-bound interleukin 15
  • the presence of the mbILl5 on theNK cell function to further enhance the cytotoxic effects of the NK cell by synergistically enhancingthe proliferation and longevity of the NK cells.
  • mbILl5 has the nucleic acid sequence of SEQ ID NO. 16.
  • mbILl5 can be truncated ormodified, such that it is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% homologous with the sequence of SEQ ID NO. 16.
  • the mbILl5 has the amino acid sequence of SEQ ID NO. 17.
  • such embodiments provide particularly effective NK cell compositions for targeting and destroying particular target cells.
  • chimeric receptors that can be generated and expressed in NK cells in order to target and destroy particular target cells, such as diseased or cancerous cells.
  • target cells such as diseased or cancerous cells.
  • Non-limiting examples of such chimeric receptors are discussed in more detail below.
  • portions of the T cell receptor complex serve as potent activators of immune signaling cascades.
  • the receptor 4-1BB a tumor necrosis factor superfamily member, activates NK cells upon ligand binding.
  • these two signaling components act in a synergistic manner to activate NK cells upon binding of a ligand to the chimeric receptor.
  • polynucleotides encoding a KG2A/CD8a/4-lBB/CD3zeta chimeric receptor, which comprises an NKG2A fragment extracellular receptor domain that binds HLA-E/peptide complex, a CD8 transmembrane region, and an effector domain comprising the signaling domains of 4-1BB and CD3zeta.
  • this chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 61.
  • the NKG2A/CD8a/4- lBB/CD3zeta chimeric receptor comprises the amino acid sequence of SEQ ID NO: 62.
  • this construct is particularly efficacious when the NK cells concurrently express mbILl5, the mbILl5 provides a further synergistic effect with respect to the activation and cytotoxic nature of the NK cells.
  • the sequence of the chimeric receptor may vary from SEQ ID NO. 61, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 61.
  • the chimeric receptor may vary from SEQ ID NO. 61, the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function.
  • polynucleotides encoding a CD94/CD8a/4-lBB/CD3zeta chimeric receptor, which comprises a CD94 fragment extracellular receptor domain, a CD8 transmembrane region, and an effector domain comprising the signaling domains of 4-1BB and CD3zeta.
  • this chimeric receptor is encoded by the nucleic acid sequence of SEQ ID NO: 59.
  • the CD94/CD8a/4- lBB/CD3zeta chimeric receptor comprises the amino acid sequence of SEQ ID NO: 60.
  • this construct is particularly efficacious when the NK cells concurrently express mbILl5, the mbILl5 provides a further synergistic effect with respect to the long-term activation and cytotoxic nature of the NK cells (e.g., in vivo persistence).
  • the sequence of the chimeric receptor may vary from SEQ ID NO. 59, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 59.
  • the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function.
  • the receptor 2B4 possesses several immunoreceptor tyrosine-based switch motifs (ITSMs) and has the potential to transduce activating signals.
  • IRSMs immunoreceptor tyrosine-based switch motifs
  • signaling through the receptor 4-1BB also activates NK cells upon ligand binding.
  • polynucleotides encoding an activating chimeric receptor which comprises an extracellular receptor domain that comprises a fragment of NKG2A, CD94, or NKG2C variant, a CD8a transmembrane region, and an effector domain comprising the signaling domains of 4-1BB and 2B4.
  • this construct can optionally be co-expressed with mbILl5.
  • combinations of 2B4 with CD3zeta are used with NK cells to generate enhanced cytotoxicity against target cells.
  • an activating chimeric receptor which comprises an extracellular receptor domain that comprises a fragment of NKG2A, CD94, or NKG2C variant, a CD8a transmembrane region, and an effector domain comprising the signaling domains of CD3zeta and 2B4.
  • this construct can optionally be co- expressed with mbILl5.
  • 4-1BB like CD3zeta and 2B4, is a potent activator of immune signaling cascades.
  • these three signaling components act in a synergistic manner to activate NK cells upon binding of a ligand to the chimeric receptor.
  • polynucleotides encoding an activating chimeric receptor which comprises an extracellular receptor domain that comprises a fragment of NKG2A, CD94, or NKG2C variant, a CD8a transmembrane region, and an effector domain comprising the signaling domains of 4-1BB and DAP 10. Additionally, in several embodiments, this construct can optionally be co-expressed with mbILl5.
  • transmembrane and effector domains (and associated function) of the activating chimeric receptor are derived from the same peptide.
  • CD 16 is a potent activating receptor expressed on the surface of NK cells.
  • polynucleotides are provided encoding a NKG2A/CD16 chimeric receptor, NKG2C variant/CD 16 chimeric receptor, or CD94/CD16 chimeric receptor, which comprises a fragment of NKG2C variant, CD94, or NKG2A, and a CD16 peptide comprising both the transmembrane region and intracellular effector domain. Additionally, in several embodiments, this construct can optionally be co-expressed with mbILl5.
  • polynucleotides are provided encoding a
  • NCR1 (NKp46), NCR2 (NKp44) and NCR3 (NKp30) are receptors on NK cells that transduce activation signals upon ligand binding.
  • polynucleotides are provided encoding a NKG2A/NCR1 chimeric receptor, CD94/NCR1 chimeric receptor, or NKG2C variant/NCRl chimeric receptor, which comprises an NKG2A, CD94, orNKG2C variant fragment, and a NCR1 peptide comprising both the transmembrane region and intracellular effector domain.
  • polynucleotides are provided encoding a
  • polynucleotides are provided encoding a NKG2A/NCR2 chimeric receptor, CD94/NCR2 chimeric receptor, NKG2C variant/NCR2 chimeric receptor, which comprises a NCR2 peptide comprising both the transmembrane region and intracellular effector domain.
  • these constructs are particularly amenable for use in creating NK cells expressing the chimeric receptor, due to their relatively small size and simplicity on sequence. However, they retain the ability, in several embodiments, to yield highly effective NK cells, despite the apparent simplicity of the construct. Additionally, in several embodiments, these constructs can optionally be co- expressed with mbILl5.
  • polynucleotides are provided encoding a
  • these constructs are particularly amenable for use in creating NK cells expressing the activating chimeric receptor, due to their relatively small size and simplicity on sequence. However, they retain the ability, in several embodiments, to yield highly effective NK cells, despite the apparent simplicity of the construct.
  • polynucleotides are provided encoding a
  • this construct can optionally be co-expressed with mbILl5.
  • polynucleotides are provided encoding a
  • this construct can optionally be co-expressed with mbILl5.
  • the surface expression and efficacy of the chimeric receptors disclosed herein are enhanced by variations in a spacer region (hinge), which, in several embodiments, are located in the extracellular domain between the transmembrane domain and any one of the CD94 fragment, NKG2A fragment, or NKG2C fragment.
  • the hinge regions can be included between other portions of the chimeric activating receptor (e.g., between intracellular and transmembrane domains, or between multiple intracellular domains).
  • domains that serve certain purposes as disclosed elsewhere herein can serve additional functions.
  • CD8a is repurposed to serve as a hinge region (encoded, in several embodiments, by the nucleic acid sequence of SEQ ID NO: 5).
  • the hinge region comprises an N- terminal truncated form of CD8a and/or a C-terminal truncated form of CD8a.
  • these truncations can be at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% homologous to the hinge encoded by SEQ ID NO. 5.
  • the hinge comprises spans of Glycine and Serine residues (herein termed“GS linkers”) where GSn represents the sequence (Gly-Gly-Gly-Gly-Ser)n (SEQ ID NO. 42).
  • the value of n may be equal to 1, 2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or greater depending on the embodiment.
  • the hinge could also be structured as GSn/CD8a.
  • the GS linker can comprise the entire hinge region.
  • the hinge region is encoded by the nucleic acid sequence of SEQ ID NO: 33.
  • the hinge region is encoded by the nucleic acid sequence of SEQ ID NO: 34.
  • the activating chimeric receptor constructs employ a 2B4 intracellular signaling domain.
  • this domain includes the amino acid sequence of SEQ ID NO. 35.
  • the 2B4 domain is encoded by the nucleic acid sequence of SEQ ID NO. 36.
  • the sequence of the 2B4 intracellular domain used in an activating chimeric receptor may vary from SEQ ID NO. 36, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 36.
  • the signaling domain of the activating chimeric receptor may vary from SEQ ID NO.
  • the activating chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function.
  • an NKp80 intracellular domain is used, in several embodiments.
  • the NKp80 domain is the sole intracellular signaling domain, while in some embodiments, that domain is used in conjunction with one or more additional domains.
  • the NKp80 is encoded by the amino acid sequence of SEQ ID NO. 37.
  • the NKp80 domain is encoded by the nucleic acid sequence of SEQ ID NO. 38.
  • the sequence of the NKp80 intracellular domain used in a chimeric receptor may vary from SEQ ID NO.
  • the chimeric receptor retains, or in some embodiments, has enhanced, NK cell activating and/or cytotoxic function.
  • the activating chimeric receptor uses a portion of a beta- adrenergic receptor as a transmembrane domain.
  • the portion comprises a portion of the beta-adrenergic extracellular domain.
  • the portion is a portion of the beta-adrenergic receptor transmembrane domain.
  • a combination of an extracellular domain and a transmembrane domain of the beta adrenergic receptor is used.
  • the portions are from the beta-l and/or beta-2 adrenergic receptor.
  • a portion of the N-terminal extracellular region of the beta-2 adrenergic receptor is used.
  • the extracellular beta-2 adrenergic domain is encoded by the nucleic acid sequence of SEQ ID NO. 40.
  • the sequence of the extracellular beta-2 adrenergic domain used in a chimeric receptor may vary from SEQ ID NO. 39, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 39.
  • the first transmembrane helix of the beta-2 adrenergic receptor is used, optionally in conjunction with the extracellular beta-2 adrenergic domain.
  • the first transmembrane helix of the beta-2 adrenergic receptor has the amino acid sequence of SEQ ID NO. 41.
  • the first transmembrane helix of the beta-2 adrenergic receptor is encoded by the nucleic acid sequence of SEQ ID NO. 42.
  • the sequence of the first transmembrane helix of the beta-2 adrenergic receptor used in a chimeric receptor may vary from SEQ ID NO. 41, but remains, depending on the embodiment, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% homologous with SEQ ID NO. 41.
  • codon optimized sequences are employed.
  • codon optimization full or partial is performed on the extracellular receptor domain comprising a fragment of a CD94, NKG2A, or NKG2C variant.
  • codon optimization is not performed.
  • a chimeric receptor construct is provided with an extracellular domain comprising a fragment of NKG2A, CD94, or NKG2C variant that is not optimized, a CD8a hinge, and a 4-1BB signaling domain.
  • a chimeric receptor construct is provided with an extracellular domain comprising a fragment of NKG2A, CD94, or NKG2C variant that is not optimized, a CD8a hinge and transmembrane domain, and a 4-1BB signaling domain.
  • an activating chimeric receptor construct is provided with an extracellular domain comprising a fragment of NKG2A, CD94, or NKG2C variant that is not optimized, a CD8a hinge, and a NKp80 signaling domain.
  • a chimeric receptor construct is provided with an extracellular domain comprising a fragment of NKG2A, CD94, or NKG2C variant that is not optimized, a CD8a hinge and transmembrane domain, and a NKp80 signaling domain.
  • a GS linker such as a GS3 linker joins the 4- 1BB and NKp80 domains.
  • a CD8 transmembrane domain is coupled with a 2B4 intracellular domain.
  • a CD8 transmembrane domain is replaced with a 2B4 domain that is transmembrane and intracellular.
  • the CD8 transmembrane domain is replaced with 2B4 and 4-1BB is expressed in a proximal
  • a CD 16 intracellular signaling domain is coupled with a CD3zeta or gamma subunit which are exogenously expressed in trans to the activating chimeric receptors described herein.
  • a CD3zeta or gamma subunit which are exogenously expressed in trans to the activating chimeric receptors described herein.
  • the activating chimeric receptors are configured to dimerize, as discussed in additional detail herein.
  • a receptor comprising a fragment of CD94, NKG2A, or NKG2C variant according to several embodiments disclosed herein is optionally dimerized. Dimerization may comprise homodimers or heterodimers, depending on the embodiment.
  • dimerization results in a shift of avidity of the activating chimeric receptor (and hence the NK cells expressing the receptor) to better ligand recognition with a coordinate balance in reduced (or lack) of adverse toxic effects.
  • the extracellular receptor domain further comprises a CD8a signal peptide.
  • the activating chimeric receptors employ internal dimers, or repeats of one or more component subunits.
  • the chimeric receptor comprises a NKG2C variant extracellular domain coupled to a second NKG2C variant extracellular domain, and a transmembrane/signaling region (or a separate transmembrane region along with a separate signaling region).
  • one or more of the extracellular domains are codon optimized.
  • the two extracellular domains are separated by a linker, for example a GSn linker.
  • a GS3 linker is used.
  • the transmembrane domain comprises an extracellular region of the beta- adrenergic receptor.
  • the transmembrane domain transmembrane domain comprises an extracellular region of the beta-2 adrenergic receptor and further comprises the first transmembrane domain of the beta-2 adrenergic receptor.
  • the signaling region comprises 4-1BB.
  • the signaling region comprises NKp80.
  • the signaling region comprises a CD 16 transmembrane-intracellular domain.
  • the signaling region comprises 4-1BB in conjunction with NKp80 or a CD 16 transmembrane-intracellular domain.
  • additional chimeric receptors employing codon optimized extracellular receptor domains are provided for (optionally, these constructs can also be replicated with non-optimized or partially optimized domains).
  • a codon optimized extracellular domain is coupled with a hinge and at least two domains (e.g. a transmembrane domain and a signaling domain).
  • the multiple signaling domains provide enhanced cytotoxic efficacy of the NK cells because multiple, non-redundant signal cascades are set in motion. While in some embodiments these multiple pathways may converge on a single signaling molecule (e.g., IFNy), the overall cytotoxic effect is unexpectedly increased because of the overall magnitude of signaling molecules driving a cytotoxic endpoint.
  • certain components of an activating chimeric receptor can be replaced with one or more additional subunits that lead to enhanced efficacy (e.g., activation or cytotoxicity of NK cells).
  • a CD 16 intracellular signaling domain can be replaced with a quad-repeat of DAP10 (e.g., 4xDAPlO).
  • a CD 16 intracellular signaling domain can be replaced with a Zap70 subunit.
  • the effector domain comprises one or more consensus hemi-ITAM sequences to enhance the transduction of activation signaling upon ligand binding.
  • the inclusion of a GS linker between the signaling domains of 4-1BB, CD16, NCR1, NCR2 and/or NCR3 enhances signal transduction.
  • one or both of CD3zeta and FcRy are additionally expressed along with the chimeric receptors described herein (either on the same or a separate construct), which results in unexpectedly enhanced signal transduction, and thus an unexpected increase in cytotoxic effects of the NK cells.
  • the engineered expression of one or more of CD3zeta and FcRy supplements endogenous expression of these molecules by NK cells, thereby further enhancing the signaling and ultimate cytotoxic potency of the NK cells.
  • any of the polynucleotides disclosed herein may also encode truncations and/or variants of one or more of the constituent subunits of an activating chimeric receptor, yet retain their ability to direct NK cells to target cells and in several embodiments unexpectedly enhance cytotoxicity upon binding.
  • any of the polynucleotides disclosed herein may also optionally include codon-optimized nucleotide sequences encoding the various constituent subunits of a chimeric receptor.
  • the terms“fragment” and“truncated” shall be given their ordinary meaning and shall also include N- and C-terminal deletion variants of proteins.
  • the polynucleotides encoding the activating chimeric receptors described herein may be inserted into vectors to achieve recombinant protein expression in NK cells.
  • the polynucleotide is operably linked to at least one regulatory element for the expression of the activating chimeric receptor.
  • transcriptional regulatory elements heterologous such as, for example an internal ribosome entry site (IRES) or enhancer element, to the peptides disclosed herein are employed to direct the transcription of the activating chimeric receptor.
  • the various constituent parts of a activating chimeric receptor can be delivered to an NK cell in a single vector, or alternatively in multiple vectors.
  • an activating chimeric receptor construct is delivered in a single vector, while another factor that enhances efficacy of the activating chimeric receptor, such as mbILl5, is delivered in a separate vector.
  • an activating chimeric receptor and a factor that enhances efficacy of the activating chimeric receptor e.g., mbILl5
  • any polynucleotide may optionally include a tag sequence, allowing identification of the presence of NK cells expressing the construct. For example, in several embodiments a FLAG tag
  • Tag sequences such as a polyhistidine tag (His-tag) (HHHHHH, SEQ ID NO. 56), HA-tag or myc-tag (EQKLISEEDL; SEQ ID NO: 57).
  • His-tag polyhistidine tag
  • HHHHHH, SEQ ID NO. 56 HHHHHH, SEQ ID NO. 56
  • HA-tag HA-tag
  • myc-tag EQKLISEEDL; SEQ ID NO: 57
  • green fluorescent protein or other fluorescent moiety, is used.
  • Combinations of tag types can also be used, to individually recognize sub-components of an activating chimeric receptor.
  • the polynucleotide encoding the activating chimeric receptor is an mRNA that may be introduced into NK cells by electroporation.
  • the vector is a virus, preferably a retrovirus, which may be introduced into NK cells by transduction.
  • the vector is a Murine Stem Cell Virus (MSCV).
  • MSCV Murine Stem Cell Virus
  • other vectors may be used, for example lentivirus, adenovirus, adeno- associated virus, and the like may be used.
  • non-HIV-derived retroviruses are used. The vector chosen will depend upon a variety of factors, including, without limitation, the strength of the transcriptional regulatory elements and the cell to be used to express a protein.
  • the vector can be a plasmid, phagemid, cosmid, viral vector, phage, artificial chromosome, and the like.
  • the vectors can be episomal, non-homologously, or homologously integrating vectors, which can be introduced into the appropriate cells by any suitable means (transformation, transfection, conjugation, protoplast fusion, electroporation, calcium phosphate-precipitation, direct microinjection, etc.) to transform them.
  • NK cells NK cells
  • SV40 early promoter region the promoter contained in the 3' long terminal repeat of Rous sarcoma virus, the herpes thymidine kinase promoter, the regulatory sequences of the metallothionein gene, an adenovirus (ADV) promoter, a cytomegalovirus (CMV) promoter, the bovine papilloma virus (BPV) promoter, the parovirus Bl9p6 promoter, the beta-lactamase promoter, the tac promoter, the nopaline synthetase promoter region or the cauliflower mosaic virus 35S RNA promoter, the promoter of ribulose biphosphate carboxylase, the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, the PGK (phosphoglycerol kinase) promoter, the synthetic MND promoter containing the U3 region
  • ADV adenovirus
  • CMV cytomegalovirus
  • Natural killer cells may be engineered to express the activating chimeric receptors disclosed herein.
  • Activating chimeric receptor expression constructs may be introduced into NK cells using any of the techniques known to one of skill in the art.
  • the activating chimeric receptors are transiently expressed in the NK cells.
  • the activating chimeric receptors are stably expressed in NK cells.
  • the NK cells are autologous cells.
  • the NK cells are donor-derived (allogeneic) cells.
  • NK cells engineered to express an activating chimeric receptor as disclosed herein, the activating chimeric receptor designed to target a marker or ligand expressed differentially on the damaged or diseased cells or tissue (e.g., expressed to a different degree as compared to a normal cell or tissue).
  • the terms“express”,“expressed” and“expression” be given their ordinary meaning and shall refer to allowing or causing the information in a gene or
  • polynucleotide sequence to become manifest for example producing a protein by activating the cellular functions involved in transcription and translation of a corresponding gene or DNA sequence.
  • the expression product itself, e.g., the resulting protein, may also be said to be “expressed” by the cell.
  • An expression product may be characterized as intracellular,
  • extracellular or transmembrane shall be given its ordinary meaning and shall refer to inside a cell.
  • extracellular shall be given its ordinary meaning and shall refer to outside a cell.
  • transmembrane shall be given its ordinary meaning and shall refer to at least a portion of a polypeptide is embedded in a cell membrane.
  • cytoplasmic shall be given its ordinary meaning and shall refer to residing within the cell membrane, outside the nucleus.
  • the terms“treat,”“treating,” and“treatment” in the context of the administration of a therapy to a subject shall be given their ordinary meaning and shall refer to the beneficial effects that a subject derives from a therapy.
  • treatment of a subject with a genetically engineered cell(s) described herein achieves one, two, three, four, or more of the following effects, including, for example: (i) reduction or amelioration the severity of disease or symptom associated therewith; (ii) reduction in the duration of a symptom associated with a disease; (iii) protection against the progression of a disease or symptom associated therewith; (iv) regression of a disease or symptom associated therewith; (v) protection against the development or onset of a symptom associated with a disease; (vi) protection against the recurrence of a symptom associated with a disease; (vii) reduction in the hospitalization of a subject; (viii) reduction in the hospitalization length; (ix) an increase in the survival of a subject with a disease; (x) a reduction in the number of symptoms associated with a disease; (xi) an enhancement, improvement, supplementation,
  • NK cells can be readily determined for a given subject based on their body mass, disease type and state, and desired aggressiveness of treatment, but range, depending on the embodiments, from about 105 cells per kg to about 1012 cells per kg (e.g., 105 - 107,
  • a dose escalation regimen is used.
  • a range of NK cells is administered, for example between about 1 x 106 cells/kg to about 1 x 108 cells/kg.
  • various types of cancer or infection disease can be treated.
  • Various embodiments provided for herein include treatment or prevention of the following non-limiting examples of cancers including, but not limited to, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), adrenocortical carcinoma, Kaposi sarcoma, lymphoma, gastrointestinal cancer, appendix cancer, central nervous system cancer, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain tumors (including but not limited to astrocytomas, spinal cord tumors, brain stem glioma, craniopharyngioma, ependymoblastoma, ependymoma, medulloblastoma, medulloepithelioma), breast cancer, bronchial tumors, Burkitt lymphoma, cervical cancer, colon cancer, chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), chronic myeloproliferative disorders, ductal carcinoma, endometrial
  • infectious diseases including, but not limited to, infections of bacterial origin may include, for example, infections with bacteria from one or more of the following genera: Bordetella , Borrelia, Brucella , Campylobacter , Chlamydia and
  • Chlamydophila Clostridium , Coryne bacterium, Enterococcus , Escherichia , Francisella , Haemophilus , Helicobacter , Legionella , Leptospira , Listeria , Mycobacterium , Mycoplasma , Neisseria , Pseudomonas , Rickettsia , Salmonella , Shigella , Staphylococcus , Streptococcus , Treponema , Vibrio , and Yersinia , and mutants or combinations thereof.
  • methods are provided to treat a variety to treat fungal infections, and such as infections of fungal origin may include, for example, infections with fungi from one or more of the following genera: Aspergillus , Blastomyces , Candida , Coccidioides, Cryptococcus , and Histoplasma , and mutants or combinations thereof.
  • methods are provided to treat a variety to treat viral infections, such as those caused by one or more viruses, such as adenovirus, Coxsackievirus, Epstein-Barr virus, hepatitis a virus, hepatitis b virus, hepatitis c virus, herpes simplex virus, type 1, herpes simplex virus, type 2, cytomegalovirus, ebola virus, human herpesvirus, type 8, HIV, influenza virus, measles virus, mumps virus, human papillomavirus, parainfluenza virus, poliovirus, rabies virus, respiratory syncytial virus, rubella virus, and varicella-zoster virus.
  • viruses such as those caused by one or more viruses, such as adenovirus, Coxsackievirus, Epstein-Barr virus, hepatitis a virus, hepatitis b virus, hepatitis c virus, herpes simplex virus, type 1, herpes simplex virus, type
  • nucleic acid and amino acid sequences that have homology of at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% (and ranges therein) as compared with the respective nucleic acid or amino acid sequences of SEQ ID NOS. 1-68 and that also exhibit one or more of the functions as compared with the respective SEQ ID NOS.
  • cytotoxic activity against cells presenting ligands to which NK cells harboring receptors encoded by the nucleic acid and amino acid sequences bind including but not limited to, (i) enhanced proliferation, (ii) enhanced activation, (iii) enhanced cytotoxic activity against cells presenting ligands to which NK cells harboring receptors encoded by the nucleic acid and amino acid sequences bind, (iv) enhanced homing to tumor or infected sites, (v) reduced off target cytotoxic effects, (vi) enhanced secretion of immunostimulatory cytokines and chemokines (including, but not limited to IFNg, TNFa, IL-22, CCL3, CCL4, and CCL5), (vii) enhanced ability to stimulate further innate and adaptive immune responses, and (viii) combinations thereof.
  • immunostimulatory cytokines and chemokines including, but not limited to IFNg, TNFa, IL-22, CCL3, CCL4, and CCL5
  • amino acid sequences that correspond to any of the nucleic acids disclosed herein, while accounting for degeneracy of the nucleic acid code.
  • those sequences that vary from those expressly disclosed herein, but have functional similarity or equivalency are also contemplated within the scope of the present disclosure.
  • the foregoing includes mutants, truncations, substitutions, or other types of modifications.
  • polynucleotides encoding activating chimeric receptors comprising an extracellular receptor domain, wherein the extracellular receptor domain comprises a fragment of CD94, NKG2A, or NKG2C variant, an effector domain comprising a transmembrane region and an intracellular signaling domain.
  • the polynucleotide encodes an effector domain comprising CD 16.
  • the polynucleotide encodes an effector domain comprising NCR1.
  • the polynucleotide encodes an effector domain comprising NCR2.
  • the polynucleotide encodes an effector domain comprising NCR3.
  • the polynucleotide encodes an additional effector domain portion comprising 4-1BB.
  • the polynucleotide encodes a chimeric receptor made up of CD 16 and a fragment of CD94, NKG2A, or NKG2C variant.
  • the polynucleotide encodes a chimeric receptor made up of NCR1 and fragment of CD94, NKG2A, or NKG2C variant.
  • the polynucleotide encodes a chimeric receptor made up of NCR2 and a fragment of CD94, NKG2A, or NKG2C variant.
  • the polynucleotide encodes a chimeric receptor made up of a fragment of CD94, NKG2A, or NKG2C variant coupled to CD16 and optionally 4-1BB.
  • CD16 is replaced by NCR1, and in some embodiments, by NCR2, or even NCR3, depending on the embodiment.
  • the effector domain further comprises a GS linker between, for example, 4-1BB and one of CD16, NCR1, NCR2, or NCR3.
  • the extracellular receptor domain further comprises a hinge region.
  • the hinge region comprises CD8a.
  • the hinge region further comprises one or more linkers, which in some
  • embodiments comprise GS9, CD8a/GS3, truncated CD8a, GS3, and the like.
  • the extracellular receptor domain further comprises a CD8a signal peptide.
  • the effector domain comprises one or more hemi-ITAM sequences.
  • the chimeric receptor does not comprise DNAX-activating protein 10 (DAP 10).
  • the chimeric receptor does not comprise an IT AM motif, but rather employs an alternative signaling region, such as an ITSM, hemi-tam or other co- stimulatory region.
  • the activating chimeric receptors described herein are co- expressed with a chimeric receptor targeting cells that express natural ligands of Natural Killer Group 2 member D (NKG2D), leading to synergistically enhanced NK cell activation and cytotoxicity.
  • NKG2D Natural Killer Group 2 member D
  • the fragment of NKG2D is encoded by a
  • polynucleotide comprising a fragment of the sequence of SEQ ID NO: 1.
  • the fragment of NKG2D comprises the sequence of SEQ ID NO: 2, while in additional embodiments, the fragment encoding NKG2D is codon optimized, and comprises, for example, the sequence of SEQ ID NO: 3.
  • the effector domain comprises one or more of CD16, NCR1, NCR2, NCR3, 4-1BB, CD28, NKp80, DAP 10, CD3zeta and 2B4. In several embodiments, these effector domains are coupled to CD8 alpha.
  • the NKG2D domain is not full-length or wild-type NKG2D and in some such embodiments, DAP 10 is not used in the chimeric receptor construct.
  • CD3Zeta or an ITAM is not used.
  • combinations of transmembrane and intracellular domains are used in several embodiments and provide for synergistic interactions between the components of the NKG2D chimeric receptor and yield enhanced cytotoxic effects.
  • linkers, hinges, or other“spacing” elements are provided for in the NKG2D chimeric receptor constructs.
  • the effector domain comprises a linker.
  • polynucleotides encode a GS linker between the portions of the NKG2D chimeric receptor construct, such as between any of 4-1BB, CD28, CD16, NCR1, NCR3, CD3zeta, DAP10, 2B4 or NKp80.
  • the NKG2D chimeric receptor effector domain comprises a linker.
  • the polynucleotides encode a GS linker between the portions of the NKG2D chimeric receptor construct, such as between any of 4-1BB, CD28, CD 16, NCR1, NCR3, 2B4 or NKp80.
  • a chimeric receptor comprising a hinge region.
  • the NKG2D chimeric receptor effector domain comprises one or more hemi-ITAM sequences. Additionally, any of chimeric receptors disclosed herein can also be co-expressed with membrane-bound interleukin 15 (mbILl5).
  • mbILl5 membrane-bound interleukin 15
  • the provided polynucleotide is an mRNA.
  • the polynucleotide is operably linked to at least one regulatory element for the expression of the activating chimeric receptor.
  • the terms“nucleic acid,” “nucleotide,” and“polynucleotide” shall be given their ordinary meanings and shall include deoxyribonucleotides, deoxyribonucleic acids, ribonucleotides, and ribonucleic acids, and polymeric forms thereof, and includes either single- or double-stranded forms.
  • Nucleic acids include naturally occurring nucleic acids, such as deoxyribonucleic acid (“DNA”) and ribonucleic acid (“RNA”) as well as nucleic acid analogs. Nucleic acid analogs include those which include non-naturally occurring bases, nucleotides that engage in linkages with other nucleotides other than the naturally occurring phosphodiester bond or which include bases attached through linkages other than phosphodiester bonds.
  • DNA deoxyribonucleic acid
  • RNA ribonucleic acid
  • nucleic acid analogs include, for example and without limitation, phosphorothioates, phosphorodithioates, phosphorotriesters, phosphoramidates, boranophosphates, methylphosphonates, chiral-methyl phosphonates, 2-O- methyl ribonucleotides, peptide-nucleic acids (PNAs), locked-nucleic acids (LNAs), and the like.
  • operably linked for example in the context of a regulatory nucleic acid sequence being“operably linked” to a heterologous nucleic acid sequence, shall be given its ordinary meaning and shall mean that the regulatory nucleic acid sequence is placed into a functional relationship with the heterologous nucleic acid sequence.
  • “operably linked to” refers to a functional linkage between a nucleic acid sequence containing an internal ribosome entry site and a heterologous coding sequence initiation in the middle of an mRNA sequence resulting in translation of the heterologous coding sequence.
  • vector shall be given its ordinary meaning and shall refer to a vehicle by which a DNA or RNA sequence (e.g., a foreign gene) can be introduced into a genetically engineered cell, so as to transform the genetically engineered cell and promote expression (e.g., transcription and/or translation) of the introduced sequence.
  • Vectors include viruses, plasmids, phages, etc.
  • chimeric receptor as used herein shall be given its ordinary meaning and shall refer to a cell- surface receptor comprising at least two polypeptide domains not naturally found together on a single protein or comprising one or more regions or portions from a different receptor or signaling molecule (e.g., another subtype or type of receptor).
  • chimeric receptor complex refers to a first polypeptide, which may comprise at least two polypeptide domains in a combination that are not naturally found together on a single protein, which first polypeptide is associated with a second polypeptide, for example, an adaptor polypeptide, a signaling molecule, or a stimulatory molecule. Additional terms relating to generation and use of chimeric receptors as disclosed here are readily understood by one of ordinary skill in the art and can also be found in International Publication WO 2014/117121 and US Patent No. 7,994,298, each of which are incorporated by reference in their entirety herein.
  • a vector comprising the polynucleotide encoding any of the polynucleotides provided for herein, wherein the
  • polynucleotides are optionally operatively linked to at least one regulatory element for expression of an activating chimeric receptor.
  • the vector is a retrovirus.
  • engineered natural killer cells comprising the
  • these NK cells are suitable for use in the treatment of prevention of disease, such as, for example, cancer and/or infectious disease.
  • the polynucleotides disclosed herein further encode a short hairpin RNA (shRNA) that specifically inhibits transcription or translation of native NKG2A, wherein the shRNA comprises a nucleotide sequence that hybridizes under stringent conditions to the native NKG2A gene, wherein the shRNA comprises a sense fragment, which comprises a nucleotide sequence substantially identical to a target sequence in the NKG2A gene that is absent in the NKG2A fragment, and an antisense fragment, wherein the sense and antisense fragments are separated by a loop fragment.
  • the polynucleotide is co-expressed with an additional construct encoding membrane-bound interleukin 15 (mbILl5).
  • the polynucleotide is an mRNA.
  • the polynucleotide is operably linked to at least one regulatory element for the expression of the activating chimeric receptor.
  • a vector comprising a polynucleotide of the present disclosure, wherein the polynucleotide is operatively linked to at least one regulatory element for expression of the activating chimeric receptor.
  • the vector is a retrovirus.
  • a method for treating or preventing cancer or an infectious disease in a mammal in need thereof comprising administering to said mammal a therapeutically effective amount of NK cells, wherein said NK cells express a activating chimeric receptor encoded by a polynucleotide according to the present disclosure.
  • the NK cells are autologous cells isolated from a patient having a cancer or an infectious disease.
  • the NK cells are allogenic cells isolated from a donor.
  • the NK cells lack surface expression of native NKG2A.
  • a polynucleotide according to the present disclosure in the manufacture of a medicament for treating or preventing cancer or an infectious disease in a mammal in need thereof.
  • a vector according the present disclosure in the manufacture of a medicament for enhancing NK cell cytotoxicity in a mammal in need thereof.
  • the vector is used in the manufacture of a medicament for treating or preventing cancer or an infectious disease in a mammal in need thereof.
  • an isolated genetically engineered natural killer cell according to the present disclosure for enhancing NK cell cytotoxicity in a mammal in need thereof.
  • an isolated genetically engineered natural killer cell according to the present disclosure for treating or preventing cancer or an infectious disease in a mammal in need thereof.
  • a chimeric Natural Killer Group 2 member C comprising an extracellular receptor domain, a transmembrane domain, and a cytoplasmic domain, wherein the extracellular receptor domain comprises SEQ ID NO. 58.
  • a chimeric receptor comprising a Natural Killer Group 2 member A (NKG2A) extracellular receptor domain, a transmembrane region, and a cytoplasmic domain.
  • the transmembrane region comprises a CD8 transmembrane region.
  • the cytoplasmic domain comprises one or more of a 4-1BB cytoplasmic domain and a CD3zeta cytoplasmic domain.
  • a polynucleotide encoding a chimeric receptor, the chimeric receptor comprising an extracellular domain, a transmembrane domain, and a cytoplasmic domain, wherein the extracellular domain comprises a Natural Killer Group 2 member C (NKG2C) and SEQ ID NO. 58.
  • NVG2C Natural Killer Group 2 member C
  • a polynucleotide encoding a chimeric receptor, the chimeric receptor comprising a Natural Killer Group 2 member A (NKG2A) extracellular receptor domain, a transmembrane region, and a cytoplasmic domain.
  • the transmembrane region comprises a CD8 transmembrane region.
  • the cytoplasmic domain comprises one or more of a 4-1BB cytoplasmic domain and a CD3zeta cytoplasmic domain.
  • the human tumor cell lines SKBR3, HT-29, ET2-OS were purchased from the American Type Culture Collection (ATCC; Rockville, MD).
  • the Ewing sarcoma cell line ES8 and EW8 were from the tissue repository of St. Jude Research Hospital (Memphis, TN).
  • Cell lines were maintained in RPMI-1640 (Therm oFisher, Waltham, MA); media were supplemented with 10% fetal bovine serum (FBS; GE Healthcare, Chicago, IL) and antibiotics.
  • FBS fetal bovine serum
  • the cell lines were transduced with a murine stem cell virus (MSCV) retroviral vector (from the Vector Development and Production Shared Resource of St. Jude Children’s Research Hospital, Memphis, TN) containing either green fluorescence protein (GFP) and luciferase.
  • MSCV murine stem cell virus
  • Peripheral blood samples were obtained from discarded anonymized by-products of platelet donations from healthy adult donors at the National University Hospital Blood Bank, Singapore.
  • Mononucleated cells were separated by centrifugation on a Lymphoprep density step (Nycomed, Oslo, Norway) and washed twice in RPMI-1640. To expand NK cells,
  • peripheral blood mononucleated cells (3 x 10 6 ) were cultured in a 6-well tissue culture plate with 2 x 10 6 irradiated (100 Gy) K562-mbl5-4lBBL cells in SCGM medium (CellGenix, Freiburg, Germany) containing lO% FBS and 40 IU/mL human interleukin (IL)-2 (Novartis, Basel, Switzerland). Every 2-3 days, fresh tissue culture medium and IL-2 was added.
  • NK cells were maintained in SCGM with FBS, antibiotics, and 400 IU/mL IL2 before the
  • NK cells were labeled with anti-NKG2A antibody conjugated to allophycocyanin (APC) and anti-APC microbeads and separated on LD column (all from Miltenyi Biotech).
  • APC allophycocyanin
  • Plasmids encoding all constructs were synthesized by Genescript (Nanjing, China).
  • a RD1 l4-pseudotyped MSCV retrovirus containing the constructs was used to transduce NK cells.
  • Retroviral vector-conditioned medium was added to RetroNectin (Takara, Otsu, Japan)-coated polypropylene tubes; after centrifugation and removal of the supernatant, expanded NK cells (3 x 10 5 ) were added to the tubes and left at 37°C for 12 hours; fresh viral supernatant was added every 12 hours for a total of 6 times.
  • Cells were then maintained in RPMI with FBS, antibiotics and 400 IU/ml of IL-2 until the time of the experiments.
  • Target cells transduced with GFP/luciferase were suspended in RPMI-1640 with 10% FBS, and plated into 96-well flat bottom plates (Costar, Corning, NY). The plates were placed in an incubator for at least 4 hours to allow for cell attachment before adding NK cells. Expanded NK cells expressing various receptors or GFP alone, suspended in RPMI-1640 with 10% FBS were then added at various effector-to-target (E:T) ratios, and co-cultured with target cells for 4 hours. At the end of the cultures, number of viable cells were measured, after adding BrightGlo (Promega, Fitchburg, WI) to the wells, using a Flx 800 plate reader (BioTek, Winooski, VT). Example 1 Activating High Affinity NKG2C Receptor Constructs
  • activating chimeric receptor constructs comprising an extracellular receptor domain coupled with various transmembrane domains are provided.
  • the present experiment was conducted to evaluate the expression and cytotoxic activity of an activating Natural Killer Group 2 member C (NKG2C) variant engineered for high affinity to HLA-E/peptide complex.
  • the activating NKG2C receptor construct was prepared and tested according to the methods and materials described above. Depending on the construct, the methods used can be readily adjusted to account for variations required for generating, expressing and testing a construct.
  • FIG. 1 A depicts a schematic showing an engineered NKG2C variant (165-168 SIIS) engineered for high affinity to HLA-E/peptide complex in a complex with CD94 and a Dap 12 dimer (termed“Dl2(SIIS)2C94” herein).
  • FIG. 1B depicts a schematic of a construct comprising NKG2C (165-168 SIIS), Dapl2, and CD94 inserted into a MSCV retroviral vector containing green fluorescence protein (GFP) after an internal ribosomal entry site (IRES).
  • GFP green fluorescence protein
  • IRS internal ribosomal entry site
  • FIG. 2 depicts flow cytometry data demonstrating the robust expression of the high affinity activating Dl2(SIIS)2C94 receptor complex in purified NKG2C(+)NKG2A(-) NK cells relative to NK cells transduced with a vector containing GFP only.
  • enhanced expression of the construct can be achieved by repeated transduction of the NK cells with a particular construct.
  • the components of the constructs can be delivered to a cell in a single vector, or alternatively using multiple vectors.
  • the construct itself may lead to enhanced expression, for example a linear or head to tail construct may yield increased expression because of a lesser degree of in-cell assembly that a multiple subunit construct requires.
  • NKG2C/CD94 and NKG2A/CD94 bind the nonclassical MHC class I molecule HLA- E/peptide complex in humans.
  • HLA-E has a very specialized role in cell recognition by NK cells, and HLA-E binds a restricted subset of peptides derived from signal peptides of classical MHC class I molecules, namely HLA-A, B, C, G. Therefore NK cells can indirectly monitor the expression of classical MHC class I molecules through the interaction of NKG2C/CD94 and NKG2A/CD94 with HLA-E/peptide complex.
  • FIG. 3 depicts the design and generation of a HLA-G signal peptide containing HLA-E molecule.
  • FIG. 3 A depicts the substitution of HLA-E signal peptide (SEQ ID NO. 69) with HLA-G signal peptide (SEQ ID NO. 70) of HLA-E (designated as GpHLA-E; HLA-G signal peptide carrying HLA-E).
  • FIG. 3B depicts flow cytometry data verifying the exogenous expression of GpHLA-E in solid tumor cell lines HT29, U20S, ES8, and EW8.
  • cytotoxicity assays were performed using cancer cell lines that express GpHLA-E.
  • Purified NKG2C(+) NKG2A(-) NK cells expressing Dl2(SIIS)2C94 displayed significantly higher cytotoxicity against U20S- GpHLA-E, SKBR3 -GpHLA-E, and HT29-GpHLA-E cells than the control NK cells at all of the E:T ratios tested (FIG. 4).
  • NK cells can not only be engineered to express activating chimeric receptor constructs, but those cells that express the activating chimeric receptor are able to be activated and successfully generate enhanced cytotoxic effects against target cells.
  • NKG2A(+) cells To confirm the depletion of NKG2A(+) cells, presence of which could potentially confound the results of these studies and NK cell-based therapies, flow cytometry analysis was conducted. Following NKG2A depletion, we confirmed that the cell population was comprised of NKG2C(+)NKG2 A(-) NK cells. Further, cytotoxicity assays of mock transduced NK cell populations or Dl2(SIIS)2C94-transduced NKG2C(+)NKG2A(-) NK cells against the genetically-modified tumor cell lines demonstrated the enhanced cytotoxicity of the latter NK cell population, regardless of whether or not cells were incubated with anti-NKG2A antibody Z199 (FIG. 5).
  • various activating chimeric receptor constructs comprising an extracellular receptor domain coupled with various transmembrane domains are provided.
  • the present experiment was conducted to evaluate the expression and cytotoxic activity of an activating Natural Killer Group 2 member A (NKG2A)/CD94 receptor construct.
  • the activating NKG2A/CD94 receptor construct was prepared and tested according to the methods and materials described above. Depending on the construct, the methods used can be readily adjusted to account for variations required for generating, expressing and testing a construct.
  • FIG. 6A depicts a schematic showing a complex comprised of truncated forms of Natural Killer Group 2 member A (NKG2A) and CD94 wherein there is a deletion of the N- terminus portion of the transmembrane and inhibitory cytoplasmic domain. These domains have been replaced with the CD8a transmembrane domain and cytoplasmic domains of 4-1BB
  • FIG. 6B depicts schematics of constructs comprising chimeric CD94 receptor and activating NKG2A receptor inserted into a MSCV retroviral vector containing green fluorescence protein (GFP) after an internal ribosomal entry site (IRES).
  • GFP green fluorescence protein
  • IRS internal ribosomal entry site
  • FIG. 7 depicts flow cytometry data demonstrating the robust expression of activating NKG2A/CD94- 4lBB-CD3z receptor in NKG2A-depleted NK cells relative to mock transduced NK cell populations.
  • NKG2A/CD94-4lBB-CD3z receptor on expanded NK cells significantly increased cytotoxicity against U20S-GpHLA-E and HT29-GpHLA-E cells in 4-hour cytotoxicity assays relative to control NK cells.
  • HT-29 cells are an immortalized colorectal
  • HT-29 cells were transduced with both GpHLA-E and luciferase, such that the HT-29 cells express HLA-E, which is a portion of the target recognized by the engineered activating receptors used in this example (the Dl2(SIIS)2C/94 construct is engineered for high affinity to an HLA-E/peptide complex (165-168 SIIS)).
  • the transduced HT-29 cells were injected intraperitoneally at a dose of 1 x 10 5 cells per mouse into each of 12 NOD-SCID IL2RGnull mice. Subsequently, NK cells (1 x 10 7 cells) were injected on day 3, 6, 10 and 13.
  • NK cells were either transduced with GFP only (“Control”) or the Dl2(SIIS)2C/94 construct. Mice also received IL-2 (20,000 IU) three times perweek by intraperitoneal injection. Ventral and dorsal bioluminescence was measured to assess tumor burden using a Xenogen Spectrum instrument (each symbol is the average of ventral and dorsal readings).
  • Dl2(SIIS)2C/94 shows very limited increase, even to the ⁇ 75 day timepoint at which the experiments were concluded.
  • a single mouse had a modest elevation of average
  • the Dl2(SIIS)2C/94 group showed significantly enhanced survival. Not only did one of the four Dl2(SIIS)2C/94 mice survive the entire duration of the experiment, the duration of survival of all of the mice in the Dl2(SIIS)2C/94 was enhanced. Statistical evaluation shows that survival in the first two groups (similar to the average bioluminescence data above).
  • Dl2(SIIS)2C/94 was significant in comparison to the No NK group as well as the NK cell receiving Control group (Kaplan Meier survival curves, log rank test, p values depicted in FIG.
  • NK cells which exhibit relatively high natural cytotoxicity
  • NK cells engineered to express activating chimeric receptors have unexpectedly elevated cytotoxic effects against target cells.
  • the expression of activating chimeric receptors on NK cells allows one or more of a reduced frequency of treatment, reduced duration of treatment, reduced required dose of NK cells, and an overall improved outcome (e.g., reduced tumor burden and/or increased survival) of a NK-based cancer immunotherapy regimen (e.g., for example as compared to treatment frequency, duration etc. using NK cells not engineered to express the high affinity domains as disclosed herein).
  • actions such as“administering a population of expanded NK cells” include“instructing the administration of a population of expanded NK cells.”
  • actions such as“administering a population of expanded NK cells” include“instructing the administration of a population of expanded NK cells.”

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)

Abstract

La présente invention concerne un polynucléotide codant pour des récepteurs chimères comprenant l'élément C du Groupe 2 de cellules tueuses naturelles (NKG2C) ayant une affinité accrue pour le complexe peptide/chaîne alpha E de l'antigène d'histocompatibilité de Classe I HLA ou un domaine récepteur extracellulaire de NKG2A couplé à un domaine effecteur. Elle porte également sur des cellules tueuses naturelles NK exprimant de telles constructions et sur l'utilisation de ces cellules NK pour induire la cytotoxicité. Elle démontre également que les cellules NK exprimant le polynucléotide codant pour NKG2C (SIIS)/CD94/DAP12 ou NKG2C/CD94/4-1 BB/CD3z présentaient une cytotoxicité NK accrue contre les cellules cancéreuses.
EP19750469.9A 2018-02-09 2019-02-07 Récepteurs chimériques activateurs et leurs utilisations dans une immunothérapie par cellules tueuses naturelles Pending EP3749685A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862628788P 2018-02-09 2018-02-09
US201862736879P 2018-09-26 2018-09-26
PCT/IB2019/000181 WO2019155288A1 (fr) 2018-02-09 2019-02-07 Récepteurs chimériques activateurs et leurs utilisations dans une immunothérapie par cellules tueuses naturelles

Publications (2)

Publication Number Publication Date
EP3749685A1 true EP3749685A1 (fr) 2020-12-16
EP3749685A4 EP3749685A4 (fr) 2021-12-22

Family

ID=67549311

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19750469.9A Pending EP3749685A4 (fr) 2018-02-09 2019-02-07 Récepteurs chimériques activateurs et leurs utilisations dans une immunothérapie par cellules tueuses naturelles

Country Status (8)

Country Link
US (1) US12258381B2 (fr)
EP (1) EP3749685A4 (fr)
JP (1) JP7360174B2 (fr)
CN (1) CN111801348A (fr)
AU (1) AU2019219454A1 (fr)
CA (1) CA3089170A1 (fr)
SG (1) SG11202007156QA (fr)
WO (1) WO2019155288A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210014210A (ko) 2014-05-15 2021-02-08 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
CA3056439A1 (fr) 2017-03-27 2018-10-04 National University Of Singapore Recepteurs chimeriques de nkg2d tronques et leurs utilisations dans une immunotherapie de cellules tueuses naturelles
AU2018245749A1 (en) 2017-03-27 2019-10-03 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
SG11202007156QA (en) 2018-02-09 2020-08-28 Nat Univ Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
US12486514B2 (en) 2018-08-29 2025-12-02 National University Of Singapore Method to specifically stimulate survival and expansion of genetically-modified immune cells
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CN120624368A (zh) * 2019-08-29 2025-09-12 克莱格医学有限公司 抗移植反应的细胞和方法
EP4028413A1 (fr) 2019-09-10 2022-07-20 Obsidian Therapeutics, Inc. Protéines de fusion de ca2-il15 pour une régulation accordable
KR20210033436A (ko) * 2019-09-18 2021-03-26 주식회사 에스엘바이젠 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도
CN114057890A (zh) * 2020-07-31 2022-02-18 南京北恒生物科技有限公司 新型共刺激结构域及其用途
CN114835820B (zh) * 2022-04-14 2023-01-06 呈诺再生医学科技(珠海横琴新区)有限公司 用于基因改造的多能干细胞及、自然杀伤细胞的嵌合型Fc受体
KR20260024373A (ko) * 2023-05-05 2026-02-20 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 다중-수용체 자연 살해 세포

Family Cites Families (243)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4844893A (en) 1986-10-07 1989-07-04 Scripps Clinic And Research Foundation EX vivo effector cell activation for target cell killing
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US6355476B1 (en) 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
DE69123241T2 (de) 1990-12-14 1997-04-17 Cell Genesys Inc Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
EP0585257A4 (fr) 1991-03-28 1995-02-22 Univ Minnesota Adn et sequence d'acide amine specifiques de cellules tueuses k naturelles.
AU6827094A (en) 1993-05-07 1994-12-12 Immunex Corporation Cytokine designated 4-1bb ligand and human receptor that binds thereto
US5906928A (en) 1993-07-30 1999-05-25 University Of Medicine And Dentistry Of New Jersey Efficient gene transfer into primary murine lymphocytes obviating the need for drug selection
US5653977A (en) 1993-09-09 1997-08-05 Uab Research Foundation Anti-idiotypic antibody that mimics the GD2 antigen
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6103521A (en) 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
DE19520729A1 (de) 1995-06-07 1996-12-12 Orpegen Pharma Gmbh Testsystem zur Erfassung der Aktivität von NK-Zellen
GB9526131D0 (en) 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US7070771B1 (en) 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US20020018783A1 (en) 1997-03-20 2002-02-14 Michel Sadelain Fusion proteins of a single chain antibody and cd28 and uses thereof
GB9713473D0 (en) 1997-06-25 1997-09-03 Celltech Therapeutics Ltd Biological products
ATE523593T1 (de) 1997-08-01 2011-09-15 Schering Corp Membranproteine aus säugetierzellen und verwandte reagentien
GB9725764D0 (en) * 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
AU741602B2 (en) 1998-02-02 2001-12-06 Johns Hopkins University School Of Medicine, The A universal immunomodulatory cytokine-expressing bystander cell line and related compositions and methods of manufacture and use
DE19813759C1 (de) 1998-03-27 1999-07-15 Gsf Forschungszentrum Umwelt Verfahren zur Induktion einer durch NK-Zellen vermittelten Immunantwort
GB9809658D0 (en) 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
EP1104455A2 (fr) 1998-06-25 2001-06-06 Hemosol Inc. Culture efficace de cellules souches permettant la production d'hemoglobine
JP2002524081A (ja) 1998-09-04 2002-08-06 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ 前立腺−特異的膜抗原に特異的な融合受容体およびその使用
WO2000023573A2 (fr) 1998-10-20 2000-04-27 City Of Hope Cellules modifiees specifiques a la molecule cd20 et utilisation de ces dernieres pour l'immunotherapie cellulaires des malignites cd20?+¿
EP1171596A1 (fr) 1999-04-16 2002-01-16 Celltech Therapeutics Limited Composants transmembranaires de synthese
WO2001029191A1 (fr) 1999-10-21 2001-04-26 Keisuke Teshigawara Methode de culture in vitro de lymphocytes et compositions de therapie genique
JP3619853B2 (ja) 1999-11-26 2005-02-16 独立行政法人理化学研究所 ナチュラルキラー細胞の増殖方法
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7329745B2 (en) 2000-06-13 2008-02-12 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
JP2002045174A (ja) 2000-07-31 2002-02-12 Inst Of Physical & Chemical Res ナチュラルキラー細胞増殖法
GB0025307D0 (en) 2000-10-16 2000-11-29 Celltech Chiroscience Ltd Biological products
CA2425862C (fr) 2000-11-07 2013-01-22 City Of Hope Cellules immunitaires specifiques a cd19 redirigees
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20030129649A1 (en) * 2001-04-24 2003-07-10 Kobilka Brian K. Conformational assays to detect binding to G protein-coupled receptors
TWI311586B (en) 2001-08-15 2009-07-01 Takara Bio Inc Method of extended culture for antigen-specific cytotoxic t lumphocytes
AU2002323236A1 (en) 2001-08-17 2003-03-03 Gerlad Elfenbein In situ immunization
US7638325B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
EP1578923A4 (fr) 2002-04-22 2009-01-21 Hutchinson Fred Cancer Res Polypeptides mic solubles utilises en tant que marqueurs pour le diagnostic, le pronostic et le traitement d'un cancer et de maladies ou d'affections auto-immunes
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2003270823A1 (en) 2002-09-19 2004-04-08 Johns Hopkins University School Of Medicine Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
GB0225279D0 (en) 2002-10-30 2002-12-11 Celltech R&D Ltd Biological products
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
EP1639001A1 (fr) 2003-06-27 2006-03-29 Dnavec Research Inc. Procede de transplantation de cellules lymphohematopoietiques chez un mammifere
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
US20050113564A1 (en) 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
WO2005118788A2 (fr) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Cellules de presentation de nouveaux antigenes artificiels, et utilisations correspondantes
EP2801583B1 (fr) 2004-07-10 2018-04-25 Fox Chase Cancer Center Lignes de cellules tueuses naturelles humaines modifiées génétiquement
WO2006036445A2 (fr) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Recepteur nk chimerique et traitement anticancereux
GB0426903D0 (en) 2004-12-08 2005-01-12 Alexis Biotech Ltd Complexes and methods
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
EP1777294A1 (fr) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Le domaine sushi de IL-15Ralpha comme enhancer sélectif et efficace de l'action de f IL-15 grâce à IL-15Rbeta/gamma, et l' hyperagoniste (IL15Ralpha sushi -IL15) comme protéine fusion
EP1945771A1 (fr) * 2005-10-28 2008-07-23 Novo Nordisk A/S Protéines de fusion se liant aux lymphocytes effecteurs et aux cellules cibles
US20070160578A1 (en) 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
US7932055B2 (en) * 2006-06-22 2011-04-26 Novo Nordisk A/S Soluble heterodimeric CD94/NKG2 receptors fusion proteins
DK2141997T3 (da) 2007-03-30 2013-02-11 Sloan Kettering Inst Cancer Konstitutiv ekspression af co-stimulatoriske ligander på adoptivt overførte t-lymfocytter
US20110059137A1 (en) 2008-03-21 2011-03-10 H. Lee Moffitt Cancer Center And Research Institutute, Inc Chemokine gene-modified cells for cancer immunotherapy
EP4032552B1 (fr) 2008-08-26 2023-10-04 City of Hope Procédé et compositions pour fonctionnement amélioré d'effecteur antitumoral de lymphocytes t
CN101684456A (zh) 2008-09-28 2010-03-31 江门罗森生物制药有限公司 一种体外培养条件下扩增人nk细胞的方法
WO2010071836A1 (fr) 2008-12-19 2010-06-24 Inserm Maturation de cellule nk et t à médiation par il-15
DK2411507T3 (da) 2009-03-26 2020-01-06 Cellprotect Nordic Pharmaceuticals Ab Ekspansion af nk-celler
NZ714757A (en) 2009-08-14 2018-07-27 Us Gov Health & Human Services Use of il-15 to increase thymic output and to treat lymphopenia
WO2011053322A1 (fr) 2009-10-30 2011-05-05 University Of Arkansas For Medical Science Utilisation de cellules effectrices autologues et d'anticorps pour le traitement d'un myélome multiple
WO2011053321A1 (fr) 2009-10-30 2011-05-05 University Of Arkansas For Medical Science Utilisation de cellules effectrices autologues pour le traitement de myélome multiple
EP2506876B1 (fr) 2009-12-02 2016-10-12 Imaginab, Inc. Minobodies j591 et cys-diabodies pour le ciblage de l'antigène membranaire spécifique de la prostate humaine (psma), et procédés d'utilisation
DK3184109T3 (da) 2009-12-29 2021-02-15 Gamida Cell Ltd Fremgangsmåder til forbedring af natural killer-cellers proliferation og aktivitet
WO2011150976A1 (fr) 2010-06-04 2011-12-08 bioMérieux Procédé et kit pour le pronostic du cancer colorectal
CN107828727A (zh) 2010-07-13 2018-03-23 人类起源公司 产生自然杀伤细胞的方法、由此获得的细胞群体及其用途
ES2602743T3 (es) 2010-09-08 2017-02-22 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Receptores de antígenos quiméricos con una región bisagra optimizada
EP2614151B1 (fr) 2010-09-08 2019-07-24 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Interleukine 15 en tant que marqueur sélectionnable pour transfert génétique dans les lymphocytes
EP3851459B1 (fr) 2010-09-21 2024-05-01 Altor BioScience, LLC Molécules de fusion multimères solubles à base d'il-15, leurs procédés de préparation et d'utilisation
CA2818684C (fr) 2010-11-22 2023-02-21 Innate Pharma Sa Traitements modulant les cellules tueuses naturelles et methodes de traitement d'hemopathies malignes
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20120321666A1 (en) 2011-05-23 2012-12-20 Cooper Laurence J N T cell therapy for b cell lymphoma
ES2716298T3 (es) 2011-09-16 2019-06-11 Baylor College Medicine El microentorno tumoral como diana mediante el uso de células NKT manipuladas
CA2848410A1 (fr) 2011-09-16 2013-03-21 The Trustees Of The University Of Pennsylvania Lymphocytes t a arn modifie pour le traitement du cancer
WO2013043196A1 (fr) 2011-09-23 2013-03-28 Bluebird Bio, Inc. Procédés de thérapie génique améliorés
ITMO20110270A1 (it) 2011-10-25 2013-04-26 Sara Caldrer Una cellula effettrice modificata per il trattamento di neoplasie esprimenti il disialonganglioside gd2
CN103294374A (zh) 2012-02-23 2013-09-11 中兴通讯股份有限公司 一种触摸屏解锁方法及装置
CN104750498B (zh) 2012-02-24 2018-12-18 青岛海信电器股份有限公司 一种控制鼠标模块的方法及电子设备
EP2866834B1 (fr) 2012-06-28 2019-05-22 University of Central Florida Research Foundation, Inc. Procédés et compositions pour des cellules tueuses naturelles
WO2014011993A2 (fr) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Extension d'épitopes en relation avec les lymphocytes t car
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
WO2014022826A2 (fr) 2012-08-03 2014-02-06 Icahn School Of Medicine At Mount Sinai Biomarqueur associé au risque de récurrence du mélanome
AR092745A1 (es) 2012-10-01 2015-04-29 Univ Pennsylvania Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
CN112458057A (zh) 2012-10-02 2021-03-09 纪念斯隆-凯特琳癌症中心 用于免疫疗法的组合物和方法
US10786532B2 (en) 2012-10-02 2020-09-29 Versiti Blood Research Institute Foundation, Inc. Method of providing cellular therapy using modified natural killer cells or T lymphocytes
WO2014055657A1 (fr) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Utilisation d'une approche trans-signalisation dans des récepteurs d'antigènes chimériques
WO2014099671A1 (fr) 2012-12-20 2014-06-26 Bluebird Bio, Inc. Récepteurs d'antigène chimériques et cellules immunitaires ciblant des malignités à cellules b
WO2014117121A1 (fr) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. Récepteur chimérique à spécificité nkg2d adapté pour être utilisé en thérapie cellulaire contre le cancer et les maladies infectieuses
PT3613439T (pt) 2013-02-15 2021-05-12 Univ California Recetor de antigénio quimérico e métodos de utilização do mesmo
EP2961831B1 (fr) 2013-02-26 2020-06-10 Memorial Sloan Kettering Cancer Center Compositions et procédés d'immunothérapie
CN103113470B (zh) 2013-02-27 2015-04-22 四川大学 靶向人egfr的基因工程化淋巴细胞及其制备方法和用途
EP2964753B1 (fr) 2013-03-07 2018-04-25 Baylor College of Medicine Ciblage de cd138 dans le cancer
WO2014164554A1 (fr) 2013-03-10 2014-10-09 Baylor College Of Medicine Cellules immunitaires résistant à la chimiothérapie
SG11201507688VA (en) 2013-03-15 2015-10-29 Sloan Kettering Inst Cancer Compositions and methods for immunotherapy
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
ES3058841T3 (en) 2013-03-15 2026-03-13 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
EP2986636B1 (fr) 2013-04-17 2018-11-14 Baylor College Of Medicine Convertisseur de signal tgf-beta immunosuppresseur
EP2997134B1 (fr) 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Application à des humains de lymphocytes t comprenant un récepteur antigénique chimérique (car)
CN105431524B (zh) 2013-06-10 2020-04-21 达娜-法勃肿瘤研究所公司 用于降低肿瘤细胞的免疫抑制的方法和组合物
US10144770B2 (en) 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
SG11201602979RA (en) 2013-10-17 2016-05-30 Univ Singapore Chimeric receptor that triggers antibody-dependent cell cytotoxicity against multiple tumors
NZ758715A (en) 2013-10-31 2023-01-27 Seattle Children’S Hospital Dba Seattle Children’S Res Institute Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
SG11201603484PA (en) 2013-11-21 2016-05-30 Ucl Business Plc Cell
SG11201605046YA (en) 2013-12-20 2016-07-28 Hutchinson Fred Cancer Res Tagged chimeric effector molecules and receptors thereof
EP3808410A1 (fr) 2013-12-20 2021-04-21 Cellectis Procédé d'ingénierie de lymphocytes t sensibles à de multiples signaux d'entrée à des fins d'immunothérapie
CN107074957B (zh) 2014-01-13 2021-05-07 希望之城公司 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
WO2015120421A1 (fr) 2014-02-10 2015-08-13 Nvigen, Inc. Nanocomposition de modulation cellulaire, et procédés d'utilisation
CN106414748B (zh) 2014-02-14 2021-05-28 得克萨斯州大学系统董事会 嵌合抗原受体及制备方法
EP3119425B1 (fr) 2014-03-15 2020-09-23 Novartis AG Récepteur d'antigène chimèrique régulable
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
WO2015154012A1 (fr) 2014-04-03 2015-10-08 Memorial Sloan-Kettering Cancer Center Populations de cellules tueuses naturelles (nk) clonogéniques et procédés de production et d'utilisation de telles populations
PL3689899T3 (pl) 2014-04-25 2022-01-31 2Seventy Bio, Inc. Chimeryczne receptory antygenowe promotora mnd
KR20210014210A (ko) 2014-05-15 2021-02-08 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
DK3151672T3 (da) 2014-06-06 2021-02-01 Bluebird Bio Inc Forbedrede t-celle-sammensætninger
EP3157958B1 (fr) 2014-06-18 2020-05-06 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Cellules nk-92 exprimant car en tant qu'agents thérapeutiques cellulaires
WO2016011210A2 (fr) 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Cellules modifiées pour thérapie cellulaire adoptive
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
AU2015301460B2 (en) 2014-08-14 2021-04-08 Novartis Ag Treatment of cancer using GFR alpha-4 chimeric antigen receptor
ES3034398T3 (en) 2014-08-28 2025-08-18 Bioatla Inc Conditionally active chimeric antigen receptors for modified t-cells
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
GB201415347D0 (en) 2014-08-29 2014-10-15 Ucl Business Plc Signalling system
CN106687584B (zh) 2014-09-04 2021-08-13 干细胞技术公司 用于t细胞或nk细胞活化和扩增的可溶性抗体复合物
KR20170073593A (ko) 2014-09-09 2017-06-28 유넘 테라퓨틱스 키메라 수용체 및 면역 요법에서의 그의 용도
WO2016042461A1 (fr) 2014-09-15 2016-03-24 Molmed Spa Récepteurs antigéniques chimériques
EP3193894A1 (fr) 2014-09-16 2017-07-26 Fundación Pública Andaluza Progreso Y Salud Utilisation de sang de cordon pour traiter les maladies médiées par les cellules nk et les maladies médiées par l'ifn-
MA41538A (fr) 2014-10-17 2017-12-26 Baylor College Medicine Cellules immunitaires bipartites et tripartites de signalisation
CN107206100B (zh) 2014-10-27 2021-02-12 弗罗里达中央大学研究基金会 自然杀伤细胞的方法和组合物
US20170333480A1 (en) 2014-11-05 2017-11-23 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
US10570186B2 (en) 2014-11-05 2020-02-25 Board Of Regents, The University Of Texas System Chimeric antigen receptors (CAR) to selectively target protein complexes
WO2016073602A2 (fr) 2014-11-05 2016-05-12 Juno Therapeutics, Inc. Procédés de transduction et de traitement de cellules
EP3018200A1 (fr) 2014-11-07 2016-05-11 Fondazione Matilde Tettamanti e Menotti de Machi Onlus Procédé amélioré pour la production de cellules génétiquement modifiées
AU2015344769B2 (en) 2014-11-12 2020-07-09 Allogene Therapeutics, Inc. Inhibitory chimeric antigen receptors
WO2016100232A1 (fr) 2014-12-15 2016-06-23 The Regents Of The University Of California Récepteur d'antigène chimère de type porte ou bispécifique sensible à cd19 et à cd20
IL320860A (en) 2014-12-19 2025-07-01 Dana Farber Cancer Inst Inc Chimeric antigen receptors and methods of using them
JP2018502115A (ja) 2014-12-31 2018-01-25 アントフロゲネシス コーポレーション ナチュラルキラー細胞及びその使用
HK1246180A1 (zh) 2014-12-31 2018-09-07 Celgene Corporation 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法
WO2016115482A1 (fr) 2015-01-16 2016-07-21 Novartis Pharma Ag Promoteurs de phosphoglycérate kinase 1 (pgk) et procédés d'utilisation pour l'expression d'un récepteur antigénique chimérique
WO2016118857A1 (fr) 2015-01-23 2016-07-28 Musc Foundation For Research Development Gènes de récepteurs de cytokines et leur utilisation pour améliorer un traitement
MA41433A (fr) 2015-01-26 2017-12-05 Baylor College Medicine Cellules immunitaires universelles pour l'immunothérapie anticancéreuse
CA2975384A1 (fr) 2015-01-29 2016-08-04 Regents Of The University Of Minnesota Recepteurs d'antigene chimere, compositions, et procedes
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
GB201501936D0 (en) 2015-02-05 2015-03-25 Ucl Business Plc Signalling system
AU2016214301B2 (en) 2015-02-06 2022-05-19 Cellectis Primary hematopoietic cells genetically engineered by slow release of nucleic acids using nanoparticles
CN113713091A (zh) 2015-02-06 2021-11-30 新加坡国立大学 工程免疫细胞及其用途和生产方法
GB201503742D0 (en) 2015-03-05 2015-04-22 Ucl Business Plc Chimeric antigen receptor
ES2979088T3 (es) 2015-03-05 2024-09-24 Fred Hutchinson Cancer Center Proteínas de fusión inmunomoduladoras y usos de las mismas
EP3064507A1 (fr) 2015-03-06 2016-09-07 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Protéines de fusion comprenant une protéine de liaison et un polypeptide interleukine-15 ayant une affinité réduite pour IL15ra et leurs utilisations thérapeutiques
US9777064B2 (en) 2015-03-17 2017-10-03 Chimera Bioengineering, Inc. Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof
US20180094280A1 (en) 2015-03-20 2018-04-05 Bluebird Bio, Inc. Vector formulations
GB201504840D0 (en) 2015-03-23 2015-05-06 Ucl Business Plc Chimeric antigen receptor
WO2016154585A1 (fr) 2015-03-26 2016-09-29 Charles Sentman Fragments de liaison à l'antigène anti-mica, molécules hybrides, cellules exprimant ceux-ci et procédés d'utilisation
JP6879932B2 (ja) 2015-04-06 2021-06-02 サイトイミューン セラピューティクス， インコーポレイテッドＣｙｔｏｉｍｍｕｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ 神経膠芽腫のためのｅｇｆｒ指向ｃａｒ療法
IL303972A (en) 2015-04-08 2023-08-01 Novartis Ag CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
US20180092968A1 (en) 2015-04-23 2018-04-05 The Trustees Of The University Of Pennsylvania Compositions to disrupt protein kinase a anchoring and uses thereof
EP3286211A1 (fr) 2015-04-23 2018-02-28 Novartis AG Traitement du cancer à l'aide de protéine récepteur antigénique chimérique et un inhibiteur de protéine kinase
GB201507108D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507104D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507111D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
GB201507119D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201507115D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
US20190031759A1 (en) 2015-04-30 2019-01-31 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
WO2016179684A1 (fr) 2015-05-11 2016-11-17 University Health Network Procédé pour la croissance de lymphocytes t régulateurs négatifs doubles
EP4218778A3 (fr) 2015-05-28 2023-08-23 Kite Pharma, Inc. Procédés de diagnostic pour thérapie par lymphocytes t
AU2016268403A1 (en) 2015-05-28 2017-12-07 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
MX2017015239A (es) 2015-05-29 2018-02-19 Juno Therapeutics Inc Composicion y metodos para regular interacciones inhibitorias en celulas geneticamente modificadas.
US11154572B2 (en) 2015-06-05 2021-10-26 Board Of Regents, The University Of Texas System Methods of treatment with natural killer cells matched for killer immunoglobulin receptor type
EP4272757A3 (fr) 2015-06-10 2023-12-27 ImmunityBio, Inc. Cellules nk-92 modifiées pour traiter le cancer
JP6961497B2 (ja) 2015-06-25 2021-11-05 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
WO2017004150A1 (fr) 2015-06-29 2017-01-05 The Johns Hopkins University Thérapie faisant intervenir des récepteurs antigéniques chimériques de point de contrôle immunitaire
JP7245647B2 (ja) 2015-07-15 2023-03-24 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法用の操作された細胞
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
CA2994412A1 (fr) 2015-07-31 2017-02-09 Memorial Sloan-Kettering Cancer Center Proteines de liaison d'antigene ciblant cd56 et leurs utilisations
HUE067376T2 (hu) 2015-08-04 2024-10-28 Xyphos Biosciences Inc Antitestek beilleszthetõ változó fragmentumai és NKG2D ligandumok módosított a1-a2 doménjei, valamint nem természetes NKG2D receptorokat megkötõ nem természetes NKG2D ligandumok
WO2017027325A1 (fr) 2015-08-07 2017-02-16 Imaginab, Inc. Constructions de liaison d'antigène se liant à des molécules cibles
GB201514874D0 (en) 2015-08-20 2015-10-07 Autolus Ltd Cell
CA2995632C (fr) 2015-08-24 2023-02-07 Cellectis Recepteurs d'antigenes chimeriques ayant des fonctions integrees pouvant etre controlees
WO2017040324A1 (fr) 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Procédés et compositions pour des cellules exprimant une molécule de signalisation intracellulaire chimérique
EP3138905A1 (fr) 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Procédé d'expansion de cellules tueuses naturelles
US11365391B2 (en) 2015-09-28 2022-06-21 Trustees Of Dartmouth College Chimeric antigen receptor anti-inflammatory cells and methods of use
US20180291080A1 (en) 2015-09-28 2018-10-11 Trustees Of Dartmouth College Chimeric antigen receptor, regulatory cells and methods of use
US11197919B2 (en) 2015-11-04 2021-12-14 City Of Hope Chimeric antigen receptors targeting HER2
MX2018005618A (es) 2015-11-05 2018-08-01 Juno Therapeutics Inc Receptores quimericos que contienen dominios inductores de traf y composiciones y metodos relacionados.
CN107109363A (zh) 2015-11-09 2017-08-29 张明杰 增强对异常细胞杀伤力的方法和药物组合物
AU2016363025B2 (en) 2015-12-03 2021-04-08 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
WO2017112877A1 (fr) 2015-12-22 2017-06-29 Icell Gene Therapeutics, Llc Récepteurs antigéniques chimériques et amélioration de l'activité anti-tumorale
JP6853514B2 (ja) 2015-12-27 2021-03-31 国立大学法人東海国立大学機構 炎症性サイトカインの産生が抑制されるキメラ抗原受容体遺伝子改変リンパ球
US11096964B2 (en) 2016-01-20 2021-08-24 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
JP7208010B2 (ja) 2016-03-29 2023-01-18 ユニバーシティ オブ サザン カリフォルニア 癌を標的とするキメラ抗原受容体
WO2017172952A1 (fr) 2016-04-01 2017-10-05 Promab Biotechnologies, Inc. Cellules car-t cd19 marquées par flag
US11596699B2 (en) 2016-04-29 2023-03-07 CureVac SE RNA encoding an antibody
CN105838677B (zh) 2016-05-20 2019-07-02 杭州优善生物科技有限公司 一种高效扩增冷冻保存nk细胞的方法及其应用
JP7591342B2 (ja) 2016-06-08 2024-11-28 プレシゲン，インコーポレイテッド Ｃｄ３３特異的キメラ抗原受容体
CN105985931A (zh) 2016-06-21 2016-10-05 黑龙江天晴干细胞股份有限公司 一种nk细胞体外扩增组合物及nk细胞扩增方法
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
SG11201810871WA (en) * 2016-07-25 2019-01-30 Us Health Methods of producing modified natural killer cells and methods of use
CA2937157A1 (fr) 2016-07-25 2018-01-25 Ucl Business Ltd Ecrasement de recepteur de cellule t fonde sur une proteine
US9916235B2 (en) 2016-08-09 2018-03-13 Seagate Technology Llc Code failure locator
WO2018057915A1 (fr) 2016-09-23 2018-03-29 The Regents Of The University Of Michigan Lymphocytes modifiés
BR112019011207A2 (pt) 2016-12-05 2019-10-08 Juno Therapeutics Inc produção de células modificadas para terapia celular adotiva
CN108148862B (zh) 2016-12-05 2019-03-08 上海优卡迪生物医药科技有限公司 一种封闭pdl1的用于抑制免疫逃脱的car-t转基因载体及其构建方法和应用
CN110121505B (zh) 2016-12-28 2023-08-01 株式会社绿十字细胞治疗 嵌合抗原受体和表达其的自然杀伤细胞
AU2018245749A1 (en) 2017-03-27 2019-10-03 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
CA3056439A1 (fr) 2017-03-27 2018-10-04 National University Of Singapore Recepteurs chimeriques de nkg2d tronques et leurs utilisations dans une immunotherapie de cellules tueuses naturelles
WO2019028051A1 (fr) 2017-07-31 2019-02-07 Lentigen Technology, Inc. Compositions et méthodes de traitement du cancer par immunothérapie anti-cd19/cd20
US11648269B2 (en) 2017-08-10 2023-05-16 National University Of Singapore T cell receptor-deficient chimeric antigen receptor T-cells and methods of use thereof
CN109554348A (zh) 2017-09-27 2019-04-02 亘喜生物科技（上海）有限公司 可诱导分泌抗cd47抗体的工程化免疫细胞
WO2019077037A1 (fr) 2017-10-18 2019-04-25 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Procédés et composés pour une thérapie par cellules immunitaires améliorées
WO2019084434A1 (fr) 2017-10-26 2019-05-02 National University Of Singapore Nouvelle approche pour la surveillance universelle d'une maladie résiduelle minimale dans la leucémie myéloïde aiguë
CN107827990B (zh) 2017-10-30 2020-07-10 河北森朗生物科技有限公司 一种多肽、编码其的核酸、其修饰的t淋巴细胞及其应用
US11866731B2 (en) 2017-11-10 2024-01-09 Chineo Medical Technology Co., Ltd Modified immune cells and uses thereof
EP3720946A4 (fr) 2017-12-08 2021-08-18 Fate Therapeutics, Inc. Immunothérapies utilisant des cellules effectrices dérivées de cspi améliorées
WO2019127215A1 (fr) * 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Récepteurs chimériques multispécifiques comprenant un domaine nkg2d et leurs procédés d'utilisation
CN109971712B (zh) 2017-12-28 2023-06-20 上海细胞治疗研究院 特异性靶向cd19抗原且高水平稳定表达pd-1抗体的car-t细胞及用途
WO2019155286A2 (fr) 2018-02-09 2019-08-15 National University Of Singapore Constructions de récepteurs d'adhésion et leurs utilisations dans une immunothérapie par cellules tueuses naturelles
SG11202007156QA (en) 2018-02-09 2020-08-28 Nat Univ Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
EP3759132A1 (fr) 2018-03-02 2021-01-06 Allogene Therapeutics, Inc. Récepteurs de cytokines chimériques inductibles
EP3765154A4 (fr) 2018-03-14 2021-11-24 Celledit LLC Modification de cellules immunitaires pour réduire la toxicité et leurs utilisations dans la thérapie cellulaire adoptive
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
AU2019253562B2 (en) 2018-04-09 2025-11-27 The Trustees Of The University Of Pennsylvania Methods and compositions comprising a viral vector for expression of a transgene and an effector
CN108840930B (zh) 2018-06-29 2021-01-26 浙江生研生物科技有限公司 抗cd19单克隆抗体及其制备方法与应用
US12486514B2 (en) 2018-08-29 2025-12-02 National University Of Singapore Method to specifically stimulate survival and expansion of genetically-modified immune cells
AU2019337603B2 (en) 2018-09-13 2026-03-05 Nkarta, Inc. Natural killer cell compositions and immunotherapy methods for treating tumors
DE102018217384A1 (de) 2018-10-11 2020-04-16 Zf Friedrichshafen Ag Innenlamellenträger für eine nasslaufende Reibkupplung
CN111088231A (zh) 2018-10-24 2020-05-01 艾生命序公司 Pd-l1抗体分泌的抗间皮素car-t细胞肿瘤免疫治疗
AU2019385873B2 (en) 2018-11-26 2026-02-05 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
EP3980450A4 (fr) 2019-06-04 2024-06-19 Nkarta, Inc. Combinaisons de cellules tueuses naturelles modifiées et de cellules t modifiées pour une immunothérapie
AU2020315213A1 (en) 2019-07-17 2022-02-03 National University Of Singapore Functional binders synthesized and secreted by immune cells
JP7724765B2 (ja) 2019-07-31 2025-08-18 ンカルタ・インコーポレイテッド ナチュラルキラー細胞の増殖を亢進する、および細胞障害性を増強するための方法および組成物
US20230028399A1 (en) 2020-01-13 2023-01-26 Nkarta, Inc. Bcma-directed cellular immunotherapy compositions and methods
AU2021286655A1 (en) 2020-06-12 2023-01-05 Nkarta, Inc. Genetically modified natural killer cells for CD70-directed cancer immunotherapy
KR20230058167A (ko) 2020-09-02 2023-05-02 엔카르타, 인크. 조작된 자연 살해 세포의 향상된 증폭 및 세포 독성 및 그의 용도
EP4482872A4 (fr) 2022-03-07 2026-03-18 Nkarta Inc Cellules éditées de gène multiplex pour immunothérapie anticancéreuse dirigée par cd70

Also Published As

Publication number Publication date
JP7360174B2 (ja) 2023-10-12
US12258381B2 (en) 2025-03-25
JP2021512615A (ja) 2021-05-20
EP3749685A4 (fr) 2021-12-22
US20210046115A1 (en) 2021-02-18
AU2019219454A1 (en) 2020-08-27
CN111801348A (zh) 2020-10-20
CA3089170A1 (fr) 2019-08-15
SG11202007156QA (en) 2020-08-28
WO2019155288A1 (fr) 2019-08-15

Similar Documents

Publication Publication Date Title
US12351617B2 (en) Immune cells comprising truncated NKG2D chimeric receptors
US12258381B2 (en) Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
AU2018202294A1 (en) Trifunctional T cell-antigen coupler and methods and uses thereof
JP6762485B2 (ja) 抗グリピカン−１−免疫抗原受容体
JP2022512475A (ja) 二量体化剤調節免疫受容体複合体
WO2022098750A1 (fr) Tcr restreints au hla de classe ii contre la mutation activant kras g12>v
CN111378046B (zh) 一种免疫效应细胞转换受体
RU2830556C2 (ru) Усеченные химерные рецепторы nkg2d и пути их применения в иммунотерапии с использованием естественных клеток-киллеров
BR122025011093A2 (pt) Polinucleotídeo que codifica um receptor quimérico, vetor, célula imune e seus usos no tratamento de câncer
WO2025191067A1 (fr) Récepteur transmembranaire chimérique comprenant au moins immunorécepteur de lymphocytes t avec une region polypeptidique des domaines ig et itim (tigit), des lymphocytes t exprimant le récepteur de commutateur tigit humain chimérique, des vecteurs avec des acides nucléiques codant pour le récepteur tigit, des kits pour préparer les lymphocytes t, ainsi que des compositions pharmaceutiques correspondantes et des méthodes pour traiter un patient ayant une maladie et pour augmenter la cytotoxicité d'un lymphocyte t dans une thérapie cellulaire adoptive
WO2025027088A1 (fr) Co-récepteur cd8 humain chimérique amélioré, acide nucléique codant pour le co-récepteur cd8 humain chimérique amélioré, vecteurs correspondants, lymphocytes t isolés transduits avec l'acide nucléique ou vecteurs correspondants et kits pour les préparer, compositions pharmaceutiques correspondantes et méthodes de traitement d'un patient atteint d'une maladie

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200908

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20211119

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20211115BHEP

Ipc: A61K 35/17 20150101ALI20211115BHEP

Ipc: C12N 5/0783 20100101ALI20211115BHEP

Ipc: C07K 14/705 20060101AFI20211115BHEP